22/03/2021
Date Journal Title Study type Country Authors Link Trial identifier Intervention Main question 8‐Mar‐2021 Lancet Infect Safety and Vaccine trial India Ella R., et al. https://www.thela NCT0447151 BBV152 To evaluate the safety Dis immunogenicity of an Phase II ncet.com/journals/ 9 (Bharat and immunogenicity of inactivated SARS‐CoV‐ laninf/article/PIIS1 Biotech) an inactivated SARS‐ 2 vaccine, BBV152: 473‐3099(21)00070‐ vaccine CoV‐2 vaccine, BBV152. interim results from a 0/fulltext double blind, randomised, multicentre, phase 2 trial, and 3‐month follow‐up of a double‐ blind, randomised phase 1 trial
4‐Mar‐2021 JAMA Effect of Ivermectin on RCT Phase III Colombia/US Lopez‐ https://jamanetwo NCT0440584 Ivermectin To determine whether Time to Resolution of A Medina E., rk.com/journals/ja 3 ivermectin is an Symptoms Among et al. ma/fullarticle/2777 efficacious treatment Adults With Mild 389 for mild COVID‐19. COVID‐19A Randomized Clinical Trial
4‐Mar‐2021 Lancet Respir Sarilumab in patients RCT Phase III International Lescure FX., https://www.thela NCT0432738 Sarilumab To assess safety and Med admitted to hospital et al. ncet.com/journals/ 8 efficacy of sarilumab, with severe or critical lanres/article/PIIS2 an interleukin‐6 COVID 19: a 213‐2600(21)00099‐ receptor inhibitor, in randomised, 0/fulltext patients with severe double blind, placebo‐ (requiring supplemental controlled, phase 3 oxygen by nasal trial cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID‐19.
4‐Mar‐2021 Lancet Azithromycin for RCT Phase III UK PRINCIPLE https://www.thela ISRCTN86534 Azithromycin To assess the community treatment Trial ncet.com/journals/ 580 effectiveness of of suspected COVID‐19 Collaborative lancet/article/PIIS0 azithromycin to treat in people at increased Group 140‐6736(21)00461‐ suspected COVID‐19 risk of an adverse X/fulltext among people in the clinical course in the community who had an UK (PRINCIPLE): a increased risk of randomised, complications. controlled, open‐label, adaptive platform trial
1‐Mar‐2021 Antimicrob Human Safety, RCT Phase IUSA Painter W. https://aac.asm.or NCT0439221 Molnupiravir Single and multiple Agents Tolerability, and P., et al. g/content/early/20 9 , EIDD‐ doses of molnupiravir Chemother Pharmacokinetics of 21/02/24/AAC.024 2801/MK‐ were evaluated in this Molnupiravir, a Novel 28‐20 4482, first‐in‐human, phase 1, Broad‐Spectrum Oral prodrug of randomized, double‐ Antiviral Agent with the active blind, Activity Against SARS‐ antiviral placebocontrolled CoV 2 ribonucleosi study in healthy de analog volunteers, which 14ß‐d‐N4‐ included evaluation of hydroxycytid the effect of food on ine (NHC; pharmacokinetics. EIDD‐1931) 11‐Mar‐2021 JAMA Immunogenicity of the Vaccine trial USA Kathryn E. Immunogenicity of NCT0443627 Ad26.COV2.S To evaluate the Ad26.COV2.S Vaccine Phase I Stephenson the Ad26.COV2.S 6 Vaccine immunogenicity of the for COVID‐19 Vaccine for COVID‐ (Janssen) Ad26.COV2.S vaccine 19 | Vaccination | (Janssen/Johnson & JAMA | JAMA Johnson) in humans, Network including the kinetics, magnitude, and phenotype of SARS‐CoV‐ 2 spike‐specific humoral and cellular immune responses.
10‐Feb‐2021 Signal Effect of human https://pubmed.nc NCT0428810 Human To assess the efficacy Transduct umbilical cord‐derived bi.nlm.nih.gov/335 2 umbilical and safety of human Target Ther mesenchymal stem 68628/ cord‐derived umbilical cord‐ cells on lung damage mesenchyma mesenchymal stem in severe COVID‐19 l stem cells cells (UC‐MSCs) to treat Vaccine trial patients: a China Shi et el. severe COVID‐19 Phase I/II randomized, double‐ patients with lung blind, placebo‐ damage, based on our controlled phase 2 trial phase 1 data.
9‐Feb‐2021 Vaccine A preliminary report of RCT phase II US LaurenceChu A preliminary NCT0440507 mRNA‐1273 To evaluate the safety a randomized report of a 6 vaccine and immunogenicity of controlled phase 2 trial randomized vaccine candidate of the safety and controlled phase 2 mRNA‐1273, encoding immunogenicity of trial of the safety the prefusion‐stabilized mRNA‐1273 SARS‐CoV‐ and spike protein of SARS‐ 2 vaccine immunogenicity of CoV‐2. mRNA‐1273 SARS‐ CoV‐2 vaccine ‐ ScienceDirect
03‐Mar‐21 Plos Med Early versus deferred RCT Chile Balcells MA https://www.ncbi. NCT0437509 Convalescent To evaluate the efficacy anti‐SARS‐CoV‐2 et al nlm.nih.gov/pmc/a 8 Plasma and safety of early convalescent plasma in rticles/PMC792956 Convalescent Plasma therapy in COVID-19 patients admitted for 8/pdf/pmed.10034 progression COVID‐19: A 15.pdf randomized phase II clinical trial 07‐Mar‐21 Thrombosis Sulodexide in the RCT Mexico Gonzalez https://pubmed.nc ISRCTN5904 Oral dose of To evaluate the effect and treatment of patients Ochoa AJ et bi.nlm.nih.gov/336 8638 sulodexide of sulodexide when Haemostasis with early stages of al 77827/ (500 LRU used in the early clinical COVID‐19: a twice a day) stages of COVID‐19 randomized controlled or placebo trial for 21 days
16‐Mar‐21 NEJM Efficacy of the RCT South Africa Madhi SA et https://www.nejm. NCT0444467 ChAdOx1 To assess the safety and ChAdOx1 nCoV‐19 al org/doi/pdf/10.105 4 nCoV‐19 efficacy of the ChAdOx1 Covid‐19 6/NEJMoa2102214 vaccine nCoV‐19 vaccine Vaccine against the ?articleTools=true (AZD1222) (AZD1222) in people B.1.351 Variant not infected with the human immunodeficiency virus (HIV) in South Africa.
https://erj.ersjournal Early use of nitazoxanide European s.com/content/erj/e Efficacy and safety of in mild Covid‐19 disease: Jan‐21 Respiratory RCT Brazil Rocco et al. arly/2021/01/04/139 NCT04552483 nitazoxanide nitrazoxanide in COVID‐19 randomised, placebo‐ Journal 93003.03725‐ patients controlled trial 2020.full.pdf
Umbilical cord mesenchymal stem cells for COVID‐19 https://stemcellsjour Stem Cell acuterespiratory distress nals.onlinelibrary.wil mesenchymal Safety of MSC in COVID‐19 Jan‐21 Transplantatio RCT USA Lanzoni et al. NCT04355728 syndrome: A double‐ ey.com/doi/epdf/10. stem cell patients n Medicine blind, phase 1002/sctm.20‐0472 1/2a,randomized controlled trial Evaluation of a SARS‐CoV‐ https://www.medrxi 2 Vaccine NVX‐CoV2373 Neil Formica v.org/content/10.11 NVX‐CoV2373 Evaluation of a SARS‐CoV‐ 1‐Mar‐21 MedRxiv RCT USA NCT04368988 in Younger and Older et al 01/2021.02.26.21252 vaccine 2 Vaccine NVX‐CoV2373 Adults 482v1.full.pdf
https://www.ncbi.nl Efficacy of favipiravir in m.nih.gov/pmc/articl Archives of COVID‐19 treatment: a Dabbous HM chloroquine To evaluate the efficacy of 25‐Jan‐21 RCT Egypt es/PMC7829645/pdf NCT04351295 Virology multi‐center randomized et al and favipiravir favipiravir /705_2021_Article_4 study 956.pdf
https://www.nejm.or NCT04381936; To evaluate the effects of Dexamethasone in Horby P et al g/doi/pdf/10.1056/N ISRCTN dexamethaso potential treatments in 25‐Feb‐21 NEJM Hospitalized Patients RCT UK (RECOVERY EJMoa2021436?articl number, ne patients hospitalized with with Covid‐19 Group) eTools=true 50189673 Covid‐19 at
To assess the efficacy and Tocilizumab in https://www.nejm.or safety of tocilizumab in Hospitalized Patients g/doi/pdf/10.1056/N 25‐Feb‐21 NEJM RCT USA Rosas IO et al NCT04320615 tocilizumab hospitalized patients with with Severe Covid‐19 EJMoa2028700?articl severe Covid‐19 Pneumonia eTools=true pneumonia
https://www.nejm.or REMAP‐CAP To assess the efficacy of Interleukin‐6 Receptor Gordon AC et g/doi/pdf/10.1056/N ClinicalTrials.g tocilizumab interleukin‐6 receptor 25‐Feb‐21 NEJM Antagonists in Critically Ill RCT UK al EJMoa2100433?articl ov number, and sarilumab antagonists in critically ill Patients with Covid‐19 eTools=true NCT02735707 patients with Covid‐19
Effect of tocilizumab on clinical outcomes at 15 Does tocilizumab days in patients with https://www.bmj.c Veiga, V.C. et improves clinical 20‐Jan‐21 BMJ severe or critical RCT Brazil om/content/372/b NCT04403685 tocilizumab al. outcomes for patients coronavirus disease mj.n84 with severe or COVID‐19?. 2019: randomised controlled tria
Interim Results of a Interim Results of a NCT04436276. The safety and Phase 1–2a Trial of vaccine Phase Phase 1–2a Trial of Ad26.COV2.S 13‐Jan‐21 NEJM USA Sadoff J., et al. opens in new immunogenicity profiles Ad26.COV2.S Covid‐19 I/IIa Ad26.COV2.S Covid‐ vaccine tab. of Ad26.COV2 Vaccine 19 Vaccine | NEJM
To assess whether convalescent plasma with high antibody levels https://www.medr rather than low antibody Early Safety Indicators of expanded xiv.org/content/10. Convalescent levels is associated with a 13‐Jan‐21 NEJM COVID‐19 Convalescent access USA Joyner et al. NCT04338360 1101/2020.05.12.2 plasma lower risk of Plasma in 5,000 Patients program 0099879v1.full.pdf death. Primary outcome: death within 30 days after plasma transfusion. Short term, high‐dose vitamin D https://pmj.bmj.co Do high doses of Postgraduate supplementation for m/content/early/2 cholecalciferol lead to 11‐Nov‐20 Medical COVID‐19 disease: a RCT India Rastogi et al. 020/11/12/postgra NCT04459247 Vitamin D SARS‐CoV‐2 negativity in Journal randomised, placebo‐ dmedj‐2020‐ greater proportions? controlled, study (SHADE 139065 study)
Safety and immunogenicity of S‐ Trimer (SCB‐2019), a https://www.thela protein subunit vaccine ncet.com/journals/ Dose‐finding and adjuvant Phase I Richmond et S‐Trimer (SCB‐ 29‐Jan‐21 The Lancet candidate for COVID‐19 Multinational lancet/article/PIIS0 NCT04405908 justification of SCB‐2019 vaccine trial al. 2019) in healthy adults: a phase 140‐6736(21)00241‐ vaccine 1, randomised, double‐ 5/fulltext blind, placebo‐controlled trial
Safety and efficacy of an rAd26 and rAd5 vector‐ https://www.thela based heterologous ncet.com/journals/ Gam‐COVID‐ prime‐boost COVID‐19 Phase III Efficacy and safety of Gam‐ 02‐Feb‐21 The Lancet Russia Logunov et al. lancet/article/PIIS0 NCT04530396 Vac (Sputnik vaccine: an interim vaccine trial COVID‐Vac V) analysis of a randomised 140‐6736(21)00234‐ controlled phase 3 trial in 8/fulltext Russia
Early High‐Titer Early High‐Titer Plasma Plasma Therapy to Does convalescent plasma Therapy to Prevent Convalescent reduce the development 06‐Jan‐21 NEJM RCT Argentina Libster R, et al. Prevent Severe NCT04479163 Severe plasma of severe respiratory Covid‐19 in Older Adults Covid‐19 in Older disease? Adults | NEJM
https://www.nejm. Efficacy, Safety, and Efficacy and Safety of the org/doi/full/10.105 mRNA‐1273 Immunogenicity of mRNA‐ Vaccine ‐ 30‐Dec‐21 NEJM mRNA‐1273 SARS‐CoV‐2 USA Baden LR, et al. 6/NEJMoa2035389 NCT04470427 SARS‐CoV‐2 1273 Vaccine in Adults phase III Vaccine ?query=featured_c Vaccine Aged 18 Years and Older oronavirus to Prevent COVID‐19
Enisamium is an inhibitor of the SARS‐CoV‐2 RNA https://www.medr polymerase and shows Efficacy and safety of Holubovska et xiv.org/content/10. 12‐Jan‐21 MedRxiv improvement of recovery RCT Multinational NCT04682873 enisamium enisamium at COVID‐19 al. 1101/2021.01.05.2 in COVID‐19 patients in patients an interim analysis of a 1249237v1.full‐text clinical trial Safety and immunogenicity of SARS‐ CoV‐2 recombinant https://www.medr protein vaccine Vaccine trial xiv.org/content/10. CoV2 preS Safety and imunogenicity 20‐Jan‐21 MedRxiv Multinational Goepfert et al. NCT04537208 formulations in healthy phase I/II 1101/2021.01.19.2 dTM vaccine of CoV2 preS dTM vaccine adults: a randomised, 0248611v1 placebo‐controlled, dose‐ ranging study
https://link.springe Pilot trial of high‐dose Annals of r.com/article/10.11 Effect of high doses of 09‐Jan‐21 vitamin C in critically ill RCT China Zhang et al. NCT04264533 Vitamin C Intensive Care 86/s13613‐020‐ vitamin C COVID‐19 patients 00792‐3
Efficacy and safety of favipiravir, an oral RNA‐ dependent RNA https://www.scien International Efficacy and safety of polymerase inhibitor, in cedirect.com/scien Journal of CTRI/2020/05 favipiravir in adults with 01‐Feb‐21 mild‐to‐moderate COVID‐ RCT India Udwadia et al. ce/article/pii/S120 favipiravir Infectious /025114 mild‐to‐moderate COVID‐ 19: A randomized, Diseases 197122032453X?vi 19 comparative, open‐label, a%3Dihub multicenter, phase 3 clinical trial
Safety and efficacy of the ChAdOx1 nCoV‐19 https://www.thela ISRCTN899514 vaccine (AZD1222) 24, ncet.com/journals/ ChAdOx1 To test the safety and against SARS‐CoV‐2: an phase I/II/III NCT04324606, 08‐Dec‐20 Lancet Multinational Voysey et al. lancet/article/PIIS0 nCoV‐19 efficacy of the ChAdOx1 interim analysis of four vaccine trial NCT04400838, vaccine nCoV‐19 vaccine randomised controlled 140‐6736(20)32661‐ and trials in Brazil, South 1/fulltext NCT04444674 Africa, and the UK
Baricitinib plus Effect of Baricitinib plus Remdesivir for baricitinib (≤14 days) plus Remdesivir for Baricitinib plus remdesivir (≤10 days) vs. 11‐Dec‐20 NEJM RCT USA Kalil A.C., et al Hospitalized Adults NCT04401579 Hospitalized Adults with Remdesivir remdesivir alone Covid‐19 with Covid‐19 | in hospitalized adults with NEJM Covid‐19
To test the safety and Tocilizumab in Patients https://www.nejm. efficacy of tocilizumab in 17‐Dec‐20 NEJM Hospitalized with Covid‐ RCT USA Salama et al. org/doi/10.1056/N NCT04372186 tocilizumab hospitalized patients with 19 Pneumonia EJMoa2030340 Covid‐19 pneumonia
Exogenous Surfactant https://assets.rese Versus Placebo in the archsquare.com/fil Treatment of Moderate Ghahremani es/rs‐ IRCT20091201 Is surfactant effective in 31‐Dec‐20 Preprint RCT Iran surfactant and Severe ARDS in et al. 136365/v1/adcad2 002804N12 COVID‐19 paients? COVID19: The Pilot Study 4b‐f7ed‐477b‐a235‐ of a Clinical Trial 235f84f8ce1b.pdf WHO mortality trial of Repurposed remdesivir, four repurposed antiviral Repurposed Antiviral Antiviral Drugs for hydroxychloro drugs — remdesivir, WHO Soidarity Drugs for Covid‐19 — Covid‐19 — Interim quine (HCQ), hydroxychloroquine 02‐Dec‐20 NEJM RCT Multinational Trial NCT04315948 Interim WHO Solidarity WHO Solidarity lopinavir, and (HCQ), lopinavir, and Consortium Trial Results Trial Results | interferon interferon beta‐1a (IFN)— NEJM beta‐1a (IFN) in patients hospitalized with Covid‐19.
Durability of mRNA 1273 vaccine Durability of Responses Responses after immunogenicity 3 months Phase I Widge A.T., et mRNA 1273 03‐Dec‐20 NEJM after SARS‐CoV‐2 USA SARS‐CoV‐2 mRNA‐ NCT04283461 after second vaccine trial al. vaccine mRNA1273 Vaccination 1273 Vaccination | vaccination NEJM
Safety and immunogenicity of INO‐ https://www.scien 4800 DNA vaccine Safety and EClinicalMedic Phase I cedirect.com/scien INO‐4800 DNA 24‐Dec‐20 against SARS‐CoV‐2: A USA/UK Tebas et al. NCT04336410 immunogenicity of INO‐ ine vaccine trial ce/article/pii/S258 vaccine preliminary report of an 4800 vaccine open‐label, Phase 1 9537020304338 clinical trial
Phase 1/2 trial of SARSCoV‐2 vaccine https://www.natur ChAdOx1 Safety and exploratory ChAdOx1 nCoV‐19 with a Phase I/II Barrett J.R., et nCoV‐19 humoral and cellular 17‐Dec‐20 Nature Med. UK e.com/articles/s41 NCT04400838 booster dose induces vaccine trial al. vaccine immunogenicity of the multifunctional antibody 591‐020‐01179‐4 AZD1222 AZD1222 vaccine responses
Interim study results: REGN‐COV2, a REGN‐COV2, a effects of high viral loads Neutralizing Neutralizing REGN‐COV2 with complications Weinreich 17‐Dec‐20 NEJM Antibody Cocktail, in RCT USA Antibody Cocktail, NCT04425629 antibody and death from D.M Outpatients with Covid‐ in Outpatients with cocktail coronavirus disease 2019 19 Covid‐19 | NEJM (Covid‐19)‐REGN‐COV2 effects on outpatients
Safety and immunogenicity clinical trial of an inactivated SARS‐CoV‐2 vaccine, https://www.medr inactivated To test the BBV152 (a phase 2, Phase I/II xiv.org/content/10. SARS‐CoV‐2 immunogenicity and 22‐Dec‐20 preprint ‐ BMJ double‐blind, India Raches et al. NCT04471519 vaccine trial 1101/2020.12.21.2 vaccine, safety of BBV152: 3 µg randomised controlled BBV152 and 6 µg with Algel‐IMDG. trial) and the persistence 0248643v1 of immune responses from a phase 1 follow‐up report A Neutralizing A Neutralizing Monoclonal To test the effect of this ACTIV‐3/TICO Monoclonal Antibody for Antibody for antibody in patients who 22‐Dec‐20 NEJM RCT Denmark LY‐CoV555 NCT04501978 LY‐CoV555 Hospitalized Patients Hospitalized are hospitalized with Study Group with Covid‐19 Patients with Covid‐ Covid‐19. 19 | NEJM
To test the effect of Efficacy of Tocilizumab on multi‐ Efficacy of Tocilizumab in Tocilizumab in organ dysfunction in a Patients Hospitalized Stone J.H., et 10‐Dec‐20 NEJM RCT USA Patients NCT04356937 tocilizumab phase 3 randomized with al controlled trial among Covid‐19 Hospitalized with Covid‐19 | NEJM hospitalized patients with COVID‐19 infection.
https://bmcinfectd Effect of Arbidol is.biomedcentral.c To determine the effect of (Umifenovir) on COVID‐ IRCT20180725 Arbidol 14‐Dec‐20 BMC Infect Dis RCT Iran Marzieh et al. om/articles/10.118 Arbidol (ARB) on COVID‐ 19: a randomized 040596N2 (Umifenovir) 19 disease. controlled trial. 6/s12879‐020‐ 05698‐w
Interferon ß‐1a (IFNß‐1a) https://trialsjourna To test the efficacy of in COVID‐19 patients l.biomedcentral.co EudraCT 2020‐ Interferon‐β‐1a (IFNβ‐1a), (INTERCOP): study Interferon ß‐ 23‐Dec‐20 Trials RCT Italy Bosi et al. m/articles/10.1186 002458‐25, in COVID‐19 patients in an protocol for a 1a (IFNß‐1a) NCT04449380 open label, randomized randomized controlled /s13063‐020‐04864‐ clinical trial. trial. 4
To evaluate the efficacy and safety of BNT162b2 is a lipid Safety and Efficacy nanoparticle–formulated, Safety and Efficacy of the NCT04368728. phase II Polack F.P., et of the BNT162b2 BNT162b2 nucleoside‐modified RNA 10‐Dec‐20 NEJM BNT162b2 mRNA Covid‐ USA opens in new vaccine trial al. mRNA Covid‐19 vaccine vaccine that encodes a 19 Vaccine tab Vaccine | NEJM prefusion stabilized, membraneanchored SARS‐ CoV‐2 fulllength spike protein.
Sofosbuvir and https://academic.o Journal of daclatasvir for the up.com/jac/advanc Is sofosbuvir/daclatasvir Antimicrobial treatment of COVID‐19 e‐ IRCT20200403 sofosbuvir, 18‐Dec‐20 RCT Iran Roozbeh et al. effective in COVID‐19 Chemotherap outpatients: a double‐ article/doi/10.1093 046926N1 daclatasvir patiets? y blind, randomized /jac/dkaa501/6041 controlled trial 772?login=true
https://journals.lw Intravenous w.com/ccejournal/ To asses the efficacy and Immunoglobulin Plus George Fulltext/2020/1100 safety of IV 16 November Critical Care Methylprednisolone Immunoglobul RCT USA Sakoulas, et 0/Intravenous_Im NCT04411667 immunoglobulin in 2020 Explorations Mitigate Respiratory ins al. hospitalized COVID‐19 Morbidity in Coronavirus munoglobulin_Plus patients. Disease 2019 _Methylprednisolo ne.14.aspx Do Zinc Supplements To evaluate the effect of Enhance the Clinical https://link.springe combining Biological Zinc, 23 November Efficacy of Sherief Abd‐ r.com/article/10.10 chloroquine/hydroxychlor Trace Element RCT Egypt NCT04447534 Hydroxychloro 2020 Hydroxychloroquine?: a Elsalam, et al. 07/s12011‐020‐ oquine and zinc in the Research quine Randomized, Multicenter 02512‐1 treatment of COVID‐19 Trial patients.
Effect of Vitamin D3 Supplementation vs To determine if vitamin Placebo on Hospital https://www.medr D3 supplementation can Length of Stay in Patients xiv.org/content/10. reduce hospital length of 17‐Nov MedRxiv RCT Brazil Murai et al. NCT04449718 Vitamin D3 with Severe COVID‐19: A 1101/2020.11.16.2 stay in hospitalized Multicenter, Double‐ 0232397v1.full.pdf patients with severe blind, Randomized 3 COVID‐19? Controlled Trial
To determine whether a single, 180 mcg Peginterferon Lambda‐1a subcutaneous dose of for treatment of https://www.medr Peginterferon Lambda‐1a outpatients with Jagannathan xiv.org/content/10. Peginterferon 23‐Nov MedRxiv RCT USA NCT04331899 (Lambda) could shorten uncomplicated COVID‐ et al. 1101/2020.11.18.2 Lambda‐1a the duration of viral 19: a randomized 0234161v1.full.pdf shedding or symptoms in placebo‐controlled trial patients with mild to moderate COVID‐19.
To evaluate the efficacy of https://www.medr convalescent plasma with Prevention of severe high titers of SARS‐CoV2 xiv.org/content/10. Convalescent 21‐Nov MedRxiv COVID‐19 in the elderly RCT Argentina Libster et al. NCT04479163 antibody administered 1101/2020.11.20.2 plasma by early hightiter plasma within 72 hours of mild 0234013v1.full.pdf symptoms to elderly patients with Covid‐19
A two‐arm, randomized, To estimate the efficacy controlled, multi‐centric, and safety of Itolizumab in open‐label Phase‐2 study https://www.medr the treatment of cytokine to evaluate the efficacy xiv.org/content/10. CTRI/2020/05 release syndrome in 02‐Dec MedRxiv RCT India Kumar et al. Itolizumab and safety of Itolizumab 1101/2020.12.01.2 /024959 patients with moderate to in moderate to severe 0239574v1.full.pdf severe acute respiratory ARDS patients due to distress syndrome (ARDS) COVID‐19 due to COVID‐19. 5‐Alpha‐Reductase Inhibitors Reduce To determine if 5‐alpha‐ Remission Time of COVID‐ https://www.medr reductase inhibitors 19: Results From a Cadegiani et xiv.org/content/10. (5ARis) are a beneficial 18‐Nov MedRxiv Randomized Double RCT Brazil, USA NCT04446429 Dutasteride al. 1101/2020.11.16.2 treatment for COVID‐19 if Blind Placebo Controlled given after SARS‐CoV‐2 Interventional Trial in 0232512v1.full.pdf infection 130 SARSCoV‐2 Positive Men
https://reader.else vier.com/reader/sd To test the effect /pii/S15675769203 Pentoxifylline (PTX) on Pentoxifylline decreases 36766?token=EDD parameters such as LDH, serum LDH levels and International 4B561C8D7F70079 lymphocyte count, days of increases lymphocyte Maldonado et 11‐Nov Immunophar RCT Mexico 3B55AFFA9EE8F0C COF‐002495 Pentoxifylline hospitalization, mortality, count in COVID‐19 al. macology and the need for patients: Results from an D28010BE3E0CADC intubation on patients external pilot study 0EF90237E4EF7333 0CF63D0FDA8F33F with severe and moderate 2F0AD9CA7536BD3 COVID‐19 3F
hydroxychloro quine, Repurposed Antiviral WHO https://www.nejm. ISRCTN839711 lopinavir/riton Drugs for Covid‐19 — effects of drugs on in‐ 02‐Dec‐20 NEJM RCT Multinational Solidarity Trial org/doi/10.1056/N 51, NCT04315 avir, Interim WHO Solidarity hospital mortality Consortium 948 interferon Trial Results EJMoa2023184 beta1, remdesivir
Does postexposure A Cluster‐Randomized https://www.nejm. prophylaxis with Trial of Hydroxychloro 24‐Nov‐20 NEJM RCT Spain Mitjà et al. org/doi/10.1056/N NCT04304053 hydroxychloroquine Hydroxychloroquine for quine prevent SARS‐CoV‐2 Prevention of Covid‐19 EJMoa2021801 infection?
Is treatment with A Randomized Trial of https://www.nejm. convalescent plasma Convalescent Plasma in Simonovich et Convalescent 24‐Nov‐20 NEJM RCT Argentina org/doi/10.1056/N NCT04383535 associated with improved Covid‐19 Severe al. plasma clinical outcomes in Pneumonia EJMoa2031304 COVID‐19 patients?
Safety and immunogenicity of ChAdOx1 nCoV‐19 https://www.scien Safety and vaccine administered in a cedirect.com/scien NCT04400838 phase II/III Ramasamy et ChAdOx1 immunogenicity of 19‐Nov‐20 The Lancet prime‐boost regimen in UK ce/article/pii/S014 , ISRCTN vaccine trial al. vaccine ChAdOx1 vaccine in young young and old adults 15281137 0673620324661?vi and old adults (COV002): a single‐blind, a%3Dihub randomised, controlled, phase 2/3 trial Safety, tolerability, and immunogenicity of an inactivated SARS‐CoV‐2 https://www.scien vaccine in healthy adults cedirect.com/scien Safety, tolerability and Lancet Infect. I/II vaccine CoronaVac 18‐Nov‐20 aged 18–59 years: a China Zhang et al. ce/article/pii/S147 NCT04352608 immunogenicity of Dis. trial vaccine randomised, double‐ 3309920308434?vi CoronaVac vaccine blind, placebo‐ a%3Dihub controlled, phase 1/2 clinical trial.
Randomized controlled trial of convalescent https://www.medr Pilot study designed to plasma therapy against Bahrain, Al Qahtani et xiv.org/content/10. Convalescent inform the design of a 04‐Nov MedRxiv RCT NCT04356534 standard therapy in 2 Ireland al. 1101/2020.11.02.2 plasma definitive phase 3 clinical patients with severe 0224303v1.full.pdf trial. COVID‐19 disease
https://www.medr To evaluate a single Peginterferon‐lambda for subcutaneous injection of xiv.org/content/10. 12/11/2020 MedRxiv the treatment of COVID‐ RCT Canada Feld et al. NCT04354259 Peginterferon peginterferon‐lambda in 1101/2020.11.09.2 19 in outpatients outpatients with COVID‐ 0228098v1.full.pdf 19.
https://reader.else vier.com/reader/sd Evaluating the effects of /pii/S15675769203 Intravenous 36729?token=13C2 To investigate the International Immunoglobulin (IVIg) on 3CAB7F2F5122293 Intravenous potential usefulness of IRCT20151227 13‐Nov Immunophar the management of RCT Iran Tabarsi et al. 6F6967643ECEC50 Immunoglobul IVIg for the management 025726N20 macology severe COVID‐19 cases: A F680C6C1B600298 in of severe cases of Covid‐ randomized controlled B1211225F0DFEC4 19. trial 733E630469CDAF7 A7C229585B41FD1 EE
Randomized Controlled To evaluate the Open Label Trial on the https://www.scien therapeutic effectiveness International Use of Favipiravir of favipiravir combined 9 November cedirect.com/scien Favipiravir, Journal of Combined with Inhaled Faryal Khamis, with inhaled interferon 2020 RCT Oman ce/article/pii/S120 NA interferon Infectious Interferon beta‐1b in et al. beta‐1b in adult patients (preprint) beta‐1b Diseases Hospitalized Patients 1971220323195?vi hospitalized with with Moderate to Severe a%3Dihub moderate to severe COVID‐19 Pneumonia COVID‐19 pneumonia.
Randomized, double‐ https://academic.o blinded and placebo‐ up.com/cid/advanc Clinical Assess the safety and controlled phase II trial of Phase 2 Yanchun Che, e‐ Inactivated Preprint Infectious China NCT04412538 immunogenitcity of this an inactivated SARS‐CoV‐ vaccine trial et al. article/doi/10.1093 vaccine Diseases inactiviated vaccine 2 vaccine in healthy /cid/ciaa1703/596 adults 2856 To evaluate the efficacy of Post‐exposure https://www.scien PEP with HCQ for the International prophylaxis with cedirect.com/scien prevention of COVID‐19 in 6 November Journal of hydroxychloroquine for Deba Prasad Hydroxychloro RCT India ce/article/pii/S092 NCT04408456 asymptomatic non‐HCW 2020 (in press) Antimicrobial the prevention of COVID‐ Dhibar, et al. quine in‐ dividuals who were at Agents 19, a myth or a reality? 4857920304350?vi risk for SARS‐CoV‐2 The PEP‐CQ Study a%3Dihub infection
To assess the safety, tolerability, and Phase 1 trial of a immunogenicity of CoVLP Candidate Recombinant https://www.medr at three dose levels Virus‐Like Particle Phase 1 Brian J Ward, xiv.org/content/10. Preprint MedRxiv Canada NCT04450004 CoVLP vaccine unadjuvanted or Vaccine for Covid‐19 vaccine Trial et al. 1101/2020.11.04.2 adjuvanted with either Disease Produced in 0226282v1 CpG 1018 or AS03 in Plants healthy adults 18 to 55 years of age.
An open‐label, randomized trial of the https://www.scien To evaluate the efficacy E‐Clinical combination of IFN‐κ plus cedirect.com/scien and safety in patients with 27 October Weihui Fu, et ChiCTR200003 IFN‐κ plus Medicine TFF2 with standard care RCT China ce/article/pii/S258 moderate COVID‐19 f the 2020 al. 0262 TFF2 (Lancet) in the treatment of 9537020302911?vi combination of IFN‐κ plus patients with moderate a%3Dihub TFF2 COVID‐19
Safety and efficacy of inhaled nebulised https://www.thela interferon beta‐1a The Lancet ncet.com/journals/ 2020‐001023‐ Efficacy and safety of (SNG001) for treatment 12‐Nov‐20 Respiratory RCT UK Monk et al. lanres/article/PIIS2 14, INF‐beta 1a inhaled nebulised of SARS‐CoV‐2 infection: Medicine NCT04385095 interferon beta‐1a a randomised, double‐ 213‐2600(20)30511‐ blind, placebo‐ 7/fulltext controlled, phase 2 trial
Determine whether Fluvoxamine vs Placebo https://jamanetwo fluvoxamine, given during and Clinical Deterioration mild COVID‐19 illness, rk.com/journals/ja 12‐Nov‐20 JAMA in Outpatients With RCT USA Lenze et al. NCT04342663 Fluvoxamine prevents clinical ma/article‐ Symptomatic COVID‐19A deterioration and Randomized Clinical Trial abstract/2773108 decreases the severity of disease
Antiviral effect of high‐ dose ivermectin in adults https://papers.ssrn with COVID‐19: a pilot .com/sol3/papers.c NCT00438188 Does ivermectin reduce Preprint The Lancet RCT Argentina Krolewiecki et al Ivermectin randomised, controlled, fm?abstract_id=37 4 the viral load? open label, multicentre 14649 trial Efficacy of Convalescent Plasma Therapy To compare the efficacy compared to Fresh https://www.medr and safety of convalescent Frozen Plasma in xiv.org/content/10. Convalescent 27‐Oct MedRxiv RCT India Bajpai et al. NCT04346446 plasma with fresh frozen Severely ill COVID‐19 1101/2020.10.25.2 plasma plasma (FFP) in severe Patients: A Pilot 0219337v1.full.pdf COVID‐19 patients Randomized Controlled Trial.
To evaluate the efficacy A placebo‐controlled Dubée et al. https://www.medr and safety of double blind trial of for the xiv.org/content/10. Hydroxychloro hydroxychloroquine in 21‐Oct MedRxiv hydroxychloroquine in RCT France NCT04325893 HYCOVID 1101/2020.10.19.2 quine adult patients with mild‐to‐ mild‐to‐moderate COVID‐ study group moderate COVID‐19 at 19 0214940v1.full.pdf risk of worsening.
To evaluate whether early Early use of nitazoxanide https://www.medr nitazoxanide therapy in mild Covid‐19 disease: xiv.org/content/10. would be effective in 23‐Oct MedRxiv RCT Brazil Rocco et al. NCT04552483 Nitazoxanide randomized, placebo 1101/2020.10.21.2 accelerating symptom controlled trial 0217208v1.full.pdf resolution in patients with mild COVID‐19.
Controlled randomized To test the combinational clinical trial on using https://www.medr therapy of Ivermectin and Ivermectin with xiv.org/content/10. Ivermectin + Doxycycline in treating 27‐Oct MedRxiv RCT Iraq Hashim et al. NCT04591600 Doxycycline for treating 1101/2020.10.26.2 Doxycycline COVID‐19 patients at COVID‐19 patients in 0219345v1.full.pdf different stages of the Baghdad, Iraq disease.
Treatment with human umbilical cord‐derived To assess the efficacy and human mesenchymal stem cells https://www.medr safety of human umbilical umbilical cord‐ for COVID‐19 patients xiv.org/content/10. cord‐mesenchymal stem 21‐Oct MedRxiv RCT China Shi et el. NCT04288102 derived with lung damage: a 1101/2020.10.15.2 cells (UC‐MSCs) to treat mesenchymal randomised, double‐ severe COVID‐19 patients 0213553v2.full.pdf stem cells blind, placebo‐controlled with lung damage. phase 2 trial
Umbilical Cord human To determine safety and Mesenchymal Stem Cells https://papers.ssrn umbilical cord‐ explore efficacy of Lancet pre‐ for COVID‐19 ARDS: A .com/sol3/papers.c 26‐Oct RCT USA Lanzoni et al. NCT04355728 derived Umbilical Cord (UC)‐MSC print Double Blind, Phase 1/2a, fm?abstract_id=36 mesenchymal infusions in COVID‐19 Randomized Controlled 96875 stem cells ARDS. Trial https://academic.o To determine whether Sofosbuvir/daclatasvir up.com/jac/advanc sofosbuvir/daclatasvir‐ regimens for the J Antimicrob e‐ sofosbuvir/da based regimens improve 01‐Nov treatment of COVID‐19: Meta‐analysis UK/Iran Simmons et al. N/A Chemother article/doi/10.1093 clatasvir clinical outcomes of an individual patient data patients with moderate or meta‐analysis /jac/dkaa418/5924 537 severe COVID‐19.
Phase 3 Trial of Coronavir https://papers.ssrn To evaluate the efficacy Lancet pre‐ (Favipiravir) in Patients Ruzhentsova .com/sol3/papers.c and safety of favipiravir 26‐Oct RCT Russia NCT04501783 Favipiravir print with Mild to Moderate et al. fm?abstract_id=36 for treatment of mild to COVID‐19 96907 moderate COVID‐19
Treatment of Coronavirus Disease https://www.scien Imunopatholo Efficacy of COVID‐19 2019 Patients with cedirect.com/scien gy and Convalescent convalescent plasma 01‐Nov‐20 Convalescent Plasma RCT USA Salazar et al. ce/article/pii/S000 infectious plasma transfusion for severe Reveals a Signal of diseases 2944020303709?vi and/or critical COVID‐19. Significantly Decreased a%3Dihub Mortality
Efficacy of Tocilizumab in https://www.nejm. Does tocilizumab prevent 21‐Oct‐20 NEJM Patients Hospitalized RCT USA Stone et al. org/doi/pdf/10.105 NCT04356937 Tocilizumab intubation or death? with Covid‐19 6/NEJMoa2028836
Effect of Tocilizumab vs https://jamanetwo To determine whether Usual Care in Adults rk.com/journals/ja tocilizumab (TCZ) JAMA Internal Hospitalized With COVID‐ improves outcomes of 20‐Oct‐20 RCT France Hermine et al. mainternalmedicin NCT04331808 Tocilizumab Medicine 19 and Moderate or patients hospitalized with Severe Pneumonia: A e/fullarticle/27721 moderate‐to‐severe Randomized Clinical Trial 87 COVID‐19 pneumonia
Effect of Tocilizumab vs https://jamanetwo NCT04346355; Standard Care on Clinical rk.com/journals/ja EudraCT To evaluate the effect of JAMA Internal Worsening in Patients 20‐Oct‐20 RCT Italy Salvarani et al. mainternalmedicin Identifier: Tocilizumab early tocilizumab Medicine Hospitalized With COVID‐ 2020‐001386‐ administration 19 PneumoniaA e/fullarticle/27721 37. Randomized Clinical Trial 86
International Efficacy of umifenovir in To evaluate the efficacy of Journal of https://pharmasco the treatment of mild Randomized Yethindra et umifenovir in mild and 01‐Oct‐20 Research in Kyrgizstan pe.org/ijrps/article NA Umifenovir and moderate covid‐19 clinical study al. moderate COVID‐19 Pharmaceutic patients /view/2839/6116 patients al Sciences
To evaluate the efficacy of Remdesivir for the https://www.nejm. remdesivir in shortening 8 October John H. Beigel, NEJM Treatment of Covid‐19 — RCT USA org/doi/10.1056/N NCT04280705 Remdesivir time to recovery in 2020 et al. Final Repor EJMoa2007764 hospitalized COVID‐19 patients. Safety and immunogenicity of an https://www.scien inactivated SARS‐CoV‐2 cedirect.com/scien To assess the safety and 15 October vaccine, BBIBP‐CorV: a Phase 1/2 Shengli Xia, et ChiCTR200003 immunogenicity of an Lancet China ce/article/pii/S147 BBIBP‐CorV 2020 randomised, double‐ vaccine trial al. 2459. inactivated SARS CoV2 blind, placebo‐ 3309920308318?vi vaccine controlled, phase 1/2 a%3Dihub trial
Lopinavir/rito Repurposed antiviral https://www.medr navir, Are repurposed andiviral 15 October drugs for COVID‐19 Hongchao xiv.org/content/10. ISRCTN839711 remdesivir, MedRiXV RCT International drugs effective in treating 2020 –interim WHO Pan, et al. 1101/2020.10.15.2 51 hydroxychloro COV ID19? SOLIDARITY trial results 0209817v1 quine, interferon
To assess the safety and dose response through SARS‐CoV‐2 Neutralizing https://www.nejm. Monoclonal reduction of viral load of 28 October Antibody LY‐CoV555 in Peter Chen, et NEJM Phase 2 RCT USA org/doi/10.1056/N NCT04427501 antibody, LY‐ monoclonal antibody LY‐ 2020 Outpatients with Covid‐ al. CoV555 CoV555 in patients with 19 EJMoa2029849 mild or moderate COVID‐ 19
To assess if a simple incentive to self‐prone for Self‐Proning in COVID‐19 https://papers.ssrn a maximum of 12 h per Patients on Low‐Flow day would decrease 21 October Lancet Aileen Kharat, .com/sol3/papers.c SNCTP000003 Oxygen Therapy: A RCT Switzerland Self‐proning oxygen needs in patients 2020 preprint et al. fm?abstract_id=36 718 Cluster Randomised admitted for COVID‐19 Controlled Trial 92538 pneumonia on low‐flow oxygen therapy.
Interim analysis of an open‐label randomized To assess if nasal irrigation International controlled trial https://onlinelibrar can reduce symptoms and 11 September Forum of evaluating nasal Kyle S. Kimura, Nasal RCT USA y.wiley.com/doi/10 NA viral shedding in mild and 2020 Allergy and irrigations in et al. irrigations moderate COVID‐19 Rhinology non‐hospitalized patients .1002/alr.22703 patients with coronavirus disease 2019
To assess the safety and Tocilizumab in https://www.medr efficacy of tocilizumab in nonventilated patients Carlos Salama, xiv.org/content/10. Preprint MedRiXV RCT USA NCT04372186 Tocilizumab patients hospitalized and hospitalized with Covid‐ et al. 1101/2020.10.21.2 non‐ventilated with Covid‐ 19 pneumonia 0210203v1 19 pneumonia. The use of intravenous immunoglobulin gamma https://bmcinfectd To evaluate the efficacy of for the treatment of BMC Naser is.biomedcentral.c intravenous 21 October severe coronavirus IRCT20200501 Immunoglobul Infectious RCT Iran Gharebaghi, om/articles/10.118 immunoglobulin (IVIg) in 2020 disease 2019: a 047259N1 in gamma Diseases et al. patients with severe randomized placebo‐ 6/s12879‐020‐ COVID‐19 infection. controlled double‐blind 05507‐4 clinical trial
Anti‐C5a antibody IFX‐1 (vilobelimab) treatment versus best supportive https://www.thela Phase 2 study to explore care for patients with ncet.com/action/s the potential benefit and 28 September Alexander P J Lancet severe COVID‐19 RCT Netherlands howPdf?pii=S2665‐ NCT04333420 Vilobelimab safety of IFX‐1 2020 Vlaar, et al. (PANAMO): an 9913%2820%2930 (vilobelimab) in patients exploratory, open‐label, 341‐6 with severe COVID‐19. phase 2 randomised controlled trial
Is the SARS CoV‐2 mRNA Safety and Evan J. https://www.nejm. 1273 safe and well 29 September Immunogenicity of SARS‐ Vaccine trial mRNA‐1273 NEJM USA Anderson, et org/doi/full/10.105 NCT04283461 tolerated in older adults 2020 CoV‐2 mRNA‐1273 Phase 1 vaccine al. and does it ellicit an Vaccine in Older Adults 6/NEJMoa2028436 immune response?
Does the BNT162b1 COVID‐19 vaccine 30 September https://www.natur vaccine elicit both BNT162b1 elicits human Vaccine trial Ugur Sahin, et BNT162b1 2020 ‐pre‐ Nature Germany e.com/articles/s41 NCT04380701 antibody and T‐cell antibody and TH1 T‐cell Phase 1 and 2 al. vaccine approved response in healthy responses 586‐020‐2814‐7 adults?
To evaluate the efficacy https://assets.rese and safety of recombinant Engineered interferon archsquare.com/fil super‐compound alpha effectively Engineered Research es/rs‐ ChiCTR200002 interferon versus Preprint improves clinical RCT China Chuan Li, et al. interferon Square 65224/v1/22886bf 9638 traditional interferon outcomes of COVID‐19 alpha alpha in patients with patients 0‐ce06‐4d42‐aeb6‐ c73ebb7c2003.pdf moderate to severe COVID‐19
https://www.scien To evaluate the efficacy Interferonβ‐1b in International Hamid cedirect.com/scien and safety of interferon 24 August treatment of severe IRCT20100228 Interferon β‐ Immunophar RCT Iran Rahmani, et ce/article/pii/S156 (IFN) β‐1b in the 2020 COVID‐19: A randomized 003449N27 1b macology al. treatment of patients with clinical trial 7576920323304?vi a%3Dihub severe COVID‐19 To evaluate the efficacy of hydroxychloroquine to Efficacy and Safety of https://jamanetwo prevent transmission of Hydroxychloroquine vs rk.com/journals/ja SARS‐CoV‐2 in hospital‐ 30 September Placebo for Pre‐exposure Benjamin S Hydroxychloro JAMA RCT USA mainternalmedicin NCT04329923 based HCWs with 2020 SARS‐CoV‐2 Prophylaxis Abella, et al. quine exposure to patients with Among Health Care e/fullarticle/27712 COVID‐19 using a pre‐ Workers 65 exposure prophylaxis strategy
Drug treatments for To compare the effects of Reed AC https://www.bmj.c 4 September covid‐19: living Systematic International treatments for BMJ Siemieniuk, et om/content/370/b NA All treatments 2020 systematic review and review collaboration coronavirus al. network meta‐analysis mj.m2980 disease 2019 (covid‐19).
To compare the rate of clinical improvement Effect of remdesivir on https://www.ncbi. among patients with patients with COVID‐19: Yokoyama et nlm.nih.gov/pmc/a COVID‐19 who received 5‐ 15‐Oct Virus Research A network meta‐analysis Meta‐analysis USA, Japan N/A Remdesivir al. rticles/PMC743751 day course of remdesivir of randomized control versus 10‐day course of trials 0/pdf/main.pdf remdesivir versus standard care.
To investigate the safety and immunogenicity of an An in‐depth investigation https://www.medr inactivated viral vaccine in of the safety and immunized individuals in a xiv.org/content/10. 06‐Sep MedRxiv immunogenicity of an Phase 1 RCT China Pu et el. NCT04412538 Vaccine phase I trial, especially 1101/2020.09.27.2 inactivated 2 SARS‐CoV‐2 focusing on safety with vaccine 0189548v1.full.pdf regard to the immunopathology of the vaccine.
Clearing the fog: Is Hydroxychloroquine https://www.medr To assess the efficacy of effective in reducing Mehmood xiv.org/content/10. Hydroxychloro HCQ in reducing disease 11‐Oct MedRxiv Corona virus disease‐ RCT Pakistan NCT04491994 Kamran et al. 1101/2020.07.30.2 quine progression in mild COVID‐ 2019 progression: A 19 randomized controlled 0165365v2.full.pdf trial
Lopinavir–ritonavir in https://www.thela Whether patients admitted to Horby et al. ncet.com/action/s ISRCTN lopinavir–ritonavir hospital with COVID‐19 lopinavir/riton 05‐Oct‐20 The Lancet RCT UK (RECOVERY howPdf?pii=S0140‐ 50189673, improves outcomes in (RECOVERY): a avir GROUP) NCT04381936 patients admitted to randomised, controlled, 6736%2820%2932 hospital with COVID‐19 open‐label, platform trial 013‐4 An open‐label, randomized trial of the https://www.scien combination of IFN‐ cedirect.com/scien Efficacy and safety of IFN‐ EClinicalMedic ChiCTR200003 20‐Sep‐20 kappa plus TFF2 with RCT China Fu et al. ce/article/pii/S258 IFN‐κ , TFF2 κ and TFF2 in COVID ine 0262 standard care in the 9537020302911?vi patients. treatment of patients a%3Dihub with moderate COVID‐19
Vaccine: non‐ Safety and replicating immunogenicity of the adenovirus 26 Ad26.COV2.S COVID‐19 https://www.medr based vector To evaluate the efficacy of vaccine candidate: Phase 1/2a Netherlands, xiv.org/content/10. 25‐Sep MedRxiv Sadoff et al. NCT04436276 expressing the a single vaccination of interim results of a phase RCT Belgium, USA 1101/2020.09.23.2 stabilized pre‐ 5x1010 vp of Ad26.COV2.S 1/2a, double‐blind, 0199604v1.full.pdf fusion spike randomized, placebo‐ protein of controlled trial SARS‐CoV‐2
To determine the Hydroxychloroquine as https://www.medr effectiveness of pre‐exposure prophylaxis hydroxychloroquine as Rajasingham xiv.org/content/10. Hydroxychloro 21‐Sep MedRxiv for COVID‐19 in RCT USA NCT04328467 pre‐exposure prophylaxis et al. 1101/2020.09.18.2 quine healthcare workers: a in healthcare workers at randomized trial 0197327v1.full.pdf high‐risk of SARS‐CoV‐2 exposure
Treatment with an Anti‐ CK2 Synthetic Peptide https://www.medr IG/CIGB300I/C Anti‐CK2 To explore safety and Improves Clinical 3 xiv.org/content/10. V/2001, Synthetic efficacy of CIGB‐325, an 22‐Sep MedRxiv Response in Covid‐19 RCT Cuba Cruz et al. 1101/2020.09.03.2 ATENEA‐Co‐ Peptide, CIGB‐ anti‐CK2 peptide, in Patients with Pneumonia. 300 trial 325 COVID‐19 patients. A Randomized and 4 0187112v2.full.pdf Controlled Clinical Trial
To compare the rate of clinical improvement Effect of remdesivir on https://www.scien among patients with patients with COVID‐19: Yujiro cedirect.com/scien COVID‐19 who received 5‐ 15‐Oct Virus Research A network meta‐analysis Meta‐analysis USA, Japan Yokoyama et ce/article/pii/S016 N/A Remdesivir day course of remdesivir of randomized control al. 8170220310443?vi versus 10‐day course of trials a%3Dihub remdesivir versus standard care.
https://academic.o Remdesivir for Severe up.com/cid/advanc Clinical NCT04292899 COVID‐19 versus a Susan A. e‐ Efficacy of remdesivir in 24 July 2020 Infectious RCT vs cohort USA and Remdesivir Cohort Receiving Olender, et al. article/doi/10.1093 COVID19 patients Diseases EUPAS34303 Standard of Care /cid/ciaa1041/587 6045 Assess the efficacy of A prospective, Antimicrobial https://aac.asm.or favipiravir in randomized, open‐label 17 November Agents Yohei Doi, et g/content/early/20 asymptomatic or mild trial of early versus late RCT Japan jRCTs0411901 Favipiravir 2020 Chemotherap al. 20/09/16/AAC.018 COVID19 patients in viral favipiravir in hospitalized 20 y clearance, and resolution patients with COVID‐19 97‐20 of symptoms
Favipiravir versus other antiviral or standard of https://virologyj.bi To evaluate the efcacy Systematic Virology care for COVID‐19 Dhan Bahadur omedcentral.com/ and safety of the drug 24‐Sep review & meta‐ Nepal N/A Favipiravir Journal treatment: a rapid Shrestha et al. articles/10.1186/s1 Favipiravir as a treatment analysis systematic review and 2985‐020‐01412‐z for COVID‐19. meta‐analysis
Therapeutic versus https://www.thro To compare therapeutic prophylactic Anna Cristina mbosisresearch.co enoxaparin treatment to 20 September Thrombosis anticoagulation for REBEC RBR‐ Enoxaparin, RCT Brazil Bertoldi m/article/S0049‐ standard prophylactic 2020 Research severe COVID‐19: A 949z6v anticoagulants Lemos, et al. anticoagulant treatment randomized phase II 3848(20)30530‐ in severe COVID19 clinical trial (HESACOVID) 2/fulltext#%20
Treatment of COVID‐19 https://academic.o To evaluate the efficacy Patients with Prolonged up.com/cid/advanc and safety of leflunomide Clinical Post‐Symptomatic Viral e‐ ChiCTR to treat COVID‐19 patients Preprint Infectious Shedding with RCT China Wang, et al Leflunomide article/doi/10.1093 2000030058 with prolonged post‐ Diseases Leflunomide ‐‐ a Single‐ symptomatic viral Center, Randomized, /cid/ciaa1417/590 shedding. Controlled Clinical Trial 9448
Effect of hydroxychloroquine with https://www.clinic To assess the effect of or without azithromycin almicrobiologyandi Chloroquine, chloroquine and Clinical Systematic 26 August on the mortality of France, Thibault nfection.com/articl hydroxychloro hydroxychloroquine with Microbiology Review and NA 2020 coronavirus disease 2019 Switzerland Fiolet, et al. e/S1198‐ quine, or without azithromycin and Infection Meta‐analysis (COVID‐19) patients: a 743X(20)30505‐ azithromycin on the mortality of COVID‐ systematic review and X/fulltext 19 patients meta‐analysis
Efficacy of commercial To evaluate and compare Chaminda https://www.medr mouth‐rinses on SARS‐ different commercial Jayampath xiv.org/content/10. Preprint MedRxIV CoV‐2 viral load in saliva: RCT Singapore NA Mouth wash moutwash solutions and Seneviratne, 1101/2020.09.14.2 Randomized Control Trial their effect on reducing et al. in Singapore 0186494v1 salivary viral load
Early Anti‐SARS‐CoV‐2 https://www.medr Evaluate the safety and Convalescent Plasma in efficacy of convalescent María Elvira xiv.org/content/10. Covalescent Preprint MedRxIV Patients Admitted for RCT Chile NCT04375098 plasma and compare an Balcells, et al. 1101/2020.09.17.2 Plasma COVID‐19: A Randomized early vs deferred Phase II Clinical Trial 0196212v1 treatement strategy Evaluate the efficacy of Effect of bromhexine on bromhexine in intensive clinical outcomes and https://bi.tbzmed. IRCT20200311 care unit (ICU) admission, 19 July 2020 Bioimpacts mortality in COVID‐19 RCT Iran Khalil Ansarin ac.ir/Article/bi‐ Bromhexine 7046797N4 mechanical ventilation, patients: A randomized 23240 and mortality in patients clinical trial with COVID‐19.
https://www.tandf Expert Review Identify studies pertaining The effect of antivirals on online.com/doi/ab of Anti‐ Systematic to antivirals in COVID‐19 12‐Sep‐20 COVID‐19: a systematic Hussain et al. UK s/10.1080/147872 NA Antivirals Infective review patients and review the review Therapy 10.2021.1823832?j clinical outcomes ournalCode=ierz20
Double‐blind, randomized, placebo‐ https://academic.o controlled trial with N‐ up.com/cid/advanc To determine whether Clinical Julio Cesar 23 September acetylcysteine for e‐ NAC in high doses can Infectious RCT Brazil Garcia de 2020 treatment of severe article/doi/10.1093 avoid respiratory failure in Diseases Alencar, et al. acute respiratory /cid/ciaa1443/591 patients with Covid‐19. syndrome caused by 0353 COVID‐19
Intravenous methylprednisolone https://erj.ersjourn pulse as a treatment for European als.com/content/e Is methylprednisolone hospitalised severe Edalatifard et IRCT20200404 Methylprednis 17‐Sep‐20 Respiratory RCT Iran arly/2020/09/09/1 effective in treatment of COVID‐19 patients: al. 046947N1 olone Journal COVID‐19 patients? results from a 3993003.02808‐ randomised controlled 2020 clinical trial
Interventions for https://journals.pl treatment of COVID‐19: A os.org/plosmedicin Effects of all treatment living systematic review 17‐Sep‐20 Plos Medicine Meta‐analysis Denmark Juul et al. e/article?id=10.137 NA NA interventions for COVID‐ with meta‐analyses and 19 trial sequential analyses 1/journal.pmed.10 (The LIVING Project) 03293
Safety and immunogenicity of an rAd26 and rAd5 vector‐ https://www.scien Safety and based heterologous cedirect.com/scien NCT04436471 immunogenicity of two 04‐Sep‐20 The Lancet prime‐boost COVID‐19 CT Russia Logunov et al. ce/article/pii/S014 and vaccine formulations (frozen and vaccine in two NCT04437875 0673620318663?vi lyophilised) of vaccine formulations: two open, a%3Dihub non‐randomised phase 1/2 studies from Russia
Safety and effectiveness https://www.scien International Can therapy with of azithromycin in cedirect.com/scien Journal of Sekhavati et HCQ+AZM reduce the 01‐Oct‐20 patients with COVID‐19: RCT Iran ce/article/pii/S092 NA azithromycine Antimicrobial al. hospital length of stay in An open‐label Agents 4857920303411?vi COVID‐19 patients? randomised trial a%3Dihub Effect of Recombinant Human Granulocyte https://jamanetwo Do increased peripheral Colony–Stimulating rk.com/journals/ja blood leukocyte and Factor for Patients With ChiCTR200003 lymphocyte cell counts 10‐Sep‐20 JAMA RCT China Cheng et al. mainternalmedicin G‐CSF Coronavirus Disease 0007 lead to clinical 2019 (COVID‐19) and e/fullarticle/27706 improvement in patients Lymphopenia: A 80 with COVID‐19? Randomized Clinical Trial
Azithromycin in addition to standard of care versus standard of care https://www.thela alone in the treatment of ncet.com/action/s Would azithromycine 04‐Sep‐20 The Lancet patients admitted to the RCT Brazil Furtado et al. howPdf?pii=S0140‐ NCT04321278 azithromycine improve clinical outcomes hospital with severe 6736%2820%2931 to COVID‐19 patiets? COVID‐19 in Brazil 862‐6 (COALITION II): a randomised clinical trial
Is the use of CQ or HCQ Chloroquine and effective and safe in Journal https://link.springe Hydroxychloroquine for Arunmozhima Chloroquine, reducing mortality and Genenral Systematic r.com/article/10.10 03‐Sep‐20 the Treatment of COVID‐ India ran Elavarasi, NA hydroxychloro improving the clinical Internal review 07/s11606‐020‐ 19: a Systematic Review et al. quine course, fever remission, Medicine and Meta‐analysis 06146‐w and virologic clearance in COVID‐19 patients?
No benefit of Diabetes & hydroxychloroquine in https://www.scien Metabolic November ‐ COVID‐19: Results of cedirect.com/scien Is HCQ effective in milde Syndrome: Systematic hydroxychloro December Systematic Review and India Pathak et al. ce/article/pii/S187 NA to moderate COVID‐19 Clinical review quine 2020 Meta‐Analysis of patients? Research & 1402120303362?vi Randomized Controlled Reviews a%3Dihub Trials"
Hydroxychloroquine use Naunyn‐ https://link.springe and progression or Schmiedeberg Systematic r.com/article/10.10 hydroxychloro Benefits and harms of 06‐Sep‐20 prognosis of COVID‐19: a China Zang et al NA 's Archives of review 07%2Fs00210‐020‐ quine HCQ in COVID‐19 patients systematic review and Pharmacology meta‐analysis 01964‐5
https://jamanetwo Effect of Dexamethasone rk.com/journals/ja on Days Alive and ma/fullarticle/2770 To determine whether Ventilator‐Free in 277?utm_campaig intravenous Patients With Moderate Bruno M. dexamethasone increases n=articlePDF&utm Dexamethaso 02‐Sep‐20 JAMA or Severe Acute RCT Brazil Tomazini, et NCT04327401 the number of ventilator‐ _medium=articleP ne Respiratory Distress al. free days among patients Syndrome and COVID‐19 DFlink&utm_sourc with COVID‐19–associated The CoDEX Randomized e=articlePDF&utm_ ARDS. Clinical Trial content=jama.2020 .17021 https://jamanetwo rk.com/journals/ja Association Between ma/fullarticle/2770 To estimate the Administration of association between 279?utm_campaig PROSPERO Systemic Corticosteroids administration of International Jonathan A.C., n=articlePDF&utm database Corticosteroid 02‐Sep‐20 JAMA and Mortality Among Meta‐analysis corticosteroids compared Collaboration et al. _medium=articleP (CRD4202019 s Critically Ill Patients With with usual care or placebo 7242) COVID‐19 ‐ A Meta‐ DFlink&utm_sourc and 28‐day all‐cause analysis e=articlePDF&utm_ mortality. content=jama.2020 .17023
https://jamanetwo rk.com/journals/ja Effect of Hydrocortisone ma/fullarticle/2770 Does low‐dose on 21‐Day Mortality or 276?utm_campaig hydrocortisone decrease Respiratory Support Pierre‐ n=articlePDF&utm Hydrocortison treatment failure in 02‐Sep‐20 JAMA Among Critically Ill RCT France François NCT02517489 _medium=articleP e patients with COVID‐ Patients With COVID‐19 ‐ Dequin, et al. 19–related acute A Randomized Clinical DFlink&utm_sourc respiratory failure? Trial e=articlePDF&utm_ content=jama.2020 .16761
https://jamanetwo rk.com/journals/ja Effect of Hydrocortisone ma/fullarticle/2770 on Mortality and Organ 278?utm_campaig To determine whether Support in Patients With Derek C. n=articlePDF&utm Hydrocortison hydrocortisone improves 02‐Sep‐20 JAMA Severe COVID‐19 The RCT UK NCT02735707 Angus, et al. _medium=articleP e outcome for patients REMAP‐CAP COVID‐19 with severe COVID‐19. Corticosteroid Domain DFlink&utm_sourc Randomized Clinical Trial e=articlePDF&utm_ content=jama.2020 .17022
Convalescent plasma in the management of To assess the moderate COVID‐19 in Anup Agarwal https://www.bmj.c effectiveness of India: An open‐label et al. and CTRI/2020/04 Convalescent 12 October 2020 BMJ RCT India om/content/371/b Convalescent plasma for parallel‐arm phase II PLACID /024775 plasma the treatment of COVID‐ multicentre randomized Collaborators mj.m3939 19 controlled trial (PLACID Trial)
To demonstrate the https://www.medr efficacy and safety of Convalescent Plasma for Convalescent Plasma used Avendaño‐ xiv.org/content/10. Convalescent 01‐Sep MedRxiv COVID‐19: A multicenter, RCT Spain NCT04345523 to prevent progression to Solà et al. 1101/2020.08.26.2 plasma randomized clinical trial severe disease or death in 0182444v3.full.pdf hospitalized patients with earlier forms of COVID‐19 Gargling with Early viral clearance 1% povidone‐ To assess the ability of among COVID‐19 Nurul https://www.medr iodine regular gargling to patients when gargling Azmawati xiv.org/content/10. 09‐Sep MedRxiv RCT Malaysia NCT04410159 (Betadine®), eliminate SARS‐CoV‐2 in with Povidone‐Iodine Mohamed et 1101/2020.09.07.2 essential oils the oropharynx and and Essential oils ‐ a al. 0180448v1.full.pdf (Listerine®) or nasopharynx. clinical trial. tap water
To investigate whether Tocilizumab in https://www.medr tocilizumab has clinical Hospitalized Patients xiv.org/content/10. 12/09/2020 MedRxiv RCT USA Rosas et al. NCT04320615 Tocilizumab benefit in hospitalized With COVID‐19 1101/2020.08.27.2 patients with severe Pneumonia 0183442v2.full.pdf COVID‐19 pneumonia.
Efficacy and safety of https://www.scien triazavirin therapy for cedirect.com/scien To assess the efficacy of ChiCTR200003 08‐Sep Engineering coronavirus disease RCT China Wu et al. ce/article/pii/S209 Triazavirin Triazavirin (TZV) for Covid‐ 00001 2019: A pilot randomized 5809920302411?vi 19 controlled trial a%3Dihub
Patient‐Reported Health Outcomes After To evaluate the efficacy of Treatment of COVID‐19 treatment with with Nebulized and/or https://assets.rese intravenous and/or Intravenous Neutral archsquare.com/fil nebulized neutral BMC neutral Electrolyzed Saline Delgado‐ es/rs‐ RPCEC000003 electrolyzed saline 10‐Sep Infectious RCT Cuba electrolyzed Combined with Usual Enciso et al. 68403/v1/e14a506 09 combined with usual Diseases. saline Medical Care Versus 7‐cd36‐4094‐9c29‐ medical care versus usual Usual Medical care 4bb66ac46805.pdf medical care alone, in alone: A Randomized, ambulatory patients with Open‐Label, Controlled COVID‐19. Trial.
Prediction of respiratory https://www.scien Computers in decompensation in Covid‐ cedirect.com/scien 01‐Sep‐20 Biology and 19 patients using RCT USA Burdick et al. ce/article/pii/S001 NCT04390516 NA NA Medicine machine learning: The 0482520302845?vi READY trial a%3Dihub
Effectiveness of https://onlinelibrar Journal of remdesivir for the y.wiley.com/doi/ab Remdesivir and its clinical 19‐Aug‐20 Medical treatment of hospitalized Review China Jiang et al. NA Remdesivir s/10.1002/jmv.264 effect Virology Covid‐19 persons: a network meta‐analysis 43 Sofosbuvir and daclatasvir compared with standard of care in https://academic.o Journal of the treatment of patients up.com/jac/advanc IS sofosbuvir and Antimicrobial admitted to hospital with e‐ sofosbuvir/da 19‐Aug‐20 RCT Iran Sadeghi et al. IRCT20200128 dalatasvir effective in Chemotherap moderate or severe article/doi/10.1093 clatasvir 046294N2 COVID patients? y coronavirus infection /jac/dkaa334/5889 (COVID‐19): a 948 randomized controlled trial
https://stemcellres Are human umbilical cord Treatment of severe Stem Cell .biomedcentral.co umbilical cord mesenchymal stem cell COVID‐19 with human ChiCTR200003 18‐Aug‐20 Research & RCT China Shu et al. m/articles/10.1186 mesenchymal infusion effective and safe umbilical cord 1494 Therapy stem cells for the treatment of mesenchymal stem cells /s13287‐020‐01875‐ 5 severe COVID?
"Effect of Calcifediol Treatment and best Available Therapy versus Evaluate the effect of Journal of https://www.scien best Available Therapy calcifediol on ICU Steroid Marta cedirect.com/scien on Intensive Care Unit admission and mortality October Biochemistry RCT Spain Entrenas ce/article/pii/S096 NCT04366908 Calcifediol Admission and Mortality among patients and Molecular Castillo, et al. Among Patients 0076020302764?vi hospitalized for COVID‐19 Biology Hospitalized for COVID‐ a%3Dihub 19: A Pilot Randomized Clinical study
Effect of an Inactivated Vaccine Against SARS‐ https://jamanetwo To assess the safety and CoV‐2 on Safety and 13 August Vaccine ‐ Shengli Xia, et rk.com/journals/ja ChiCTR200003 Inactivated immunogenicity of this JAMA Immunogenicity China 2020 Phase I and II al. ma/fullarticle/2769 1809 vaccine whole virus inactivated Outcomes Interim vaccine Analysis of 2 Randomized 612 Clinical Trials
Effect of Remdesivir vs https://jamanetwo Standard Care on Clinical Effect of remdesivir in 21 August Christoph D. rk.com/journals/ja JAMA Status at 11 Days in RCT USA NCT04292730 Remdesivir patients with moderate 2020 Spinner, et al. ma/fullarticle/2769 Patients With Moderate COVID19 COVID‐19 871
Drug treatments for Reed AC https://www.bmj.c Living systematic review covid‐19: living Systematic International 30 July 2020 BMJ Siemieniuk, et om/content/370/b NA All treatments and network meta‐ systematic review and Review Collaboration al. analysis network meta‐analysis mj.m2980 RNA‐Based COVID‐19 https://www.medr Vaccine: RNA To assess the safety and Vaccine BNT162b2 USA/ xiv.org/content/10. vaccines immunogenicity of varying 28‐Aug MedRXiv RCT Walsh et al. NCT04368728 Selected for a Pivotal Germany 1101/2020.08.17.2 BNT162b1 and dose levels of vaccines Efficacy Study 0176651v2.full.pdf BNT162b2 BNT162b1 and BNT162b2.
Methylprednisolone as Adjunctive Therapy for https://academic.o Patients Hospitalized Christiane up.com/cid/advanc Assess the efficacy of Clinical 12 August With COVID‐19 Maria Prado e‐ Methylprednis short‐term Infectious RCT Brazil NCT04343729 2020 (Metcovid): A Jeronimo, et article/doi/10.1093 olone methylprednisolone in Diseases Randomised, Double‐ al. /cid/ciaa1177/589 patients with COVID‐19 Blind, Phase IIb, Placebo‐ 1816 Controlled Trial
AVIFAVIR for Treatment https://academic.o Assess the efficacy and of Patients with up.com/cid/advanc safety of favipiravir in Clinical Andrey A. 09 August Moderate COVID‐19: e‐ moderate COVID19 and Infectious RCT Russia Ivashchenko, NCT04434248 Favipiravir 2020 Interim Results of a article/doi/10.1093 select the optimal dosing Diseases et al. Phase II/III Multicenter /cid/ciaa1176/589 regimen for further Randomized Clinical Trial 0024 evaluation (Phase III).
SARS‐CoV‐2 Clearance in https://www.scien Efficacy of Novaferon and International COVID‐19 Patients with cedirect.com/scien Novaferon + Journal of Fang Zheng, et ChiCTR200002 Preprint Novaferon Treatment: A China ce/article/pii/S120 Novaferon Lopinavir/ritonavir in Infectious al. 9496 Randomized, Open‐label, moderate and severe Diseases 197122030597X?vi Parallel Group Trial a%3Dihub COVID19.
Telmisartan for https://www.medr Assess the anti‐ treatment of Covid‐19 Mariano xiv.org/content/10. inflammatory effect of Preprint medRxiv patients: an open RCT Argentina NCT04355936 Telmisartan Duarte, et al. 1101/2020.08.04.2 telmisartan in COVID‐19 randomized clinical trial. patients Preliminary report. 0167205v2
Auxora versus standard of care for the treatment https://ccforum.bi of severe or critical Safety and tolerability of 14 August Joseph Miller, omedcentral.com/ Critical Care COVID‐19 pneumonia: RCT USA NCT04345614. Auxora auxora in severe or critical 2020 et al. articles/10.1186/s1 results from a COVID‐19 randomized controlled 3054‐020‐03220‐x trial
Immunogenicity and Safety of a SARS‐CoV‐2 Inactivated Vaccine in https://www.medr Healthy Adults Aged 18‐ Is this SARS CoV 2 Phase II Yanjun Zhang, xiv.org/content/10. Inactiviated Preprint medRxiv 59 years: Report of the China NCT04352608 inactivated vaccine safe vaccine RCT et al. 1101/2020.07.31.2 Vaccine Randomized, Double‐ and well tolerated? blind, and Placebo‐ 0161216v1 controlled Phase 2 Clinical Trial Beneficial effects of colchicine for moderate https://www.medr To evaluate the efficacy of to severe COVID‐19: an Maria IF xiv.org/content/10. colcihcine in treating Preprint medRxiv interim analysis of a RCT Brazil RBR‐8jyhxh Colchicine Lopes, et al. 1101/2020.08.06.2 severe and moderate randomized, double‐ COVID‐19 blinded, placebo 0169573v2 controlled clinical trial
Assess the safety and Phase 1–2 Trial of a SARS‐ NVX‐CoV2373; https://www.nejm. tolerability of the NVX‐ 2 September CoV‐2 Recombinant Phase I Cheryl Keech, recombinant NEJM Australia org/doi/full/10.105 NCT04368988 COV2373 recombinant 2020 Spike Protein vaccine RCT et al. nanoparticle vaccine in healthy Nanoparticle Vaccine 6/NEJMoa2026920 vaccine subjects.
Asses the efficacy of Hydroxychloroquine with Alexandre B. https://www.nejm. hydroxychloroquine with or without Azithromycin Hydroxychloro 23 July 2020 NEMJ RCT Brazil Cavalcanti, et org/doi/10.1056/N NCT04322123 and without azithromycin in Mild‐to‐Moderate quine al. in mild to moderate Covid‐19 EJMoa2019014 COVID19
Hydroxychloro quine, Systematic Review and Tocilizumab, Meta‐analysis of Viveksandeep https://onlinelibrar Journal of Remdesivir, Asses overall efficacy of Effectiveness of Systematic Thoguluva y.wiley.com/doi/ep 6 July 2020 Medical USA NA convalescent treatments that have Treatment Options review Chandrasekar, df/10.1002/jmv.26 Virology plasma, been studied thus far. Against SARS‐CoV‐2 et al. 302 steroids, infection lopinavir/riton avir
Use of a humanized anti‐ https://www.medr Is itolizumab a safe and CD6 monoclonal Yayquier Díaz, xiv.org/content/10. RPCEC000003 efficient treatment for Preprint medRxiv antibody (itolizumab) in CT Cuba Itolizumab et al. 1101/2020.07.24.2 11 COVID 19 in elderley elderly patients with patients? moderate COVID‐19 0153833v1
Efficacy and tolerability https://www.medr Is bevacizumab a safe and of bevacizumab in Jiaojiao Pang, xiv.org/content/10. Preprint medRxiv CT China, Italy NCT04275414 Bevacizumab efficient treatment for patients with severe et al 1101/2020.07.26.2 severe COVID 19? Covid ‐19 0159756v1
A clinical pilot study on To evaluate the efficacy the safety and efficacy of https://www.scien and safety of intranasal EClinicalMedic aerosol inhalation cedirect.com/scien ChiCTR200003 IFN‐κ plus 29 July 2020 CT China + USA Weihui et al. inhalation of TFF2 and IFN‐ ine (Lancet) treatment of IFN‐κ plus ce/article/pii/S258 0262 trefoil factor 2 κ protein for SARS‐CoV‐2 TFF2 in patients with 9537020302224 infection moderate COVID‐19
A Small‐Scale Medication https://link.springe of Leflunomide as a Virologica r.com/article/10.10 ChiCTR Is leflunomide effective in 21 July 2020 Treatment of COVID‐19 CT China Hu et al. leflunomide Sinica 07%2Fs12250‐020‐ 2000030058 COVID‐19 patients? in an Open‐Label Blank‐ Controlled Clinical Trial 00258‐7 Safety and To assess the immunogenicity of the Folegatti et al. https://www.thela immunogenicity, ChAdOx1 nCoV‐19 on behalf of ncet.com/journals/ ISRCTN ChAdOx1 reactogenicity, and safety vaccine against SARS‐CoV‐ 20‐Jul Lancet RCT UK the Oxford lancet/article/PIIS0 15281137; nCoV‐19 of vaccination with 2: a preliminary report of COVID Vaccine NCT04324606 vaccine ChAdOx1 nCoV‐19 in a phase 1/2, single‐blind, 140‐6736(20)31604‐ Trial Group single‐dose and two‐dose randomised controlled 4/fulltext regimens. trial
Immunogenicity and safety of a recombinant Phase 2 trial to further adenovirus type‐5‐ https://www.thela adenovirus evaluate the vectored COVID‐19 ncet.com/action/s type‐5 (Ad5)‐ immunogenicity and Feng‐Cai Zhu 20‐Jul Lancet vaccine in healthy adults RCT China howPdf?pii=S0140‐ NCT04341389 vectored safety in a larger et al. aged 18 years or older: a 6736%2820%2931 COVID‐19 population, and to randomised, double‐ 605‐6 vaccine determine an appropriate blind, placebo‐ dose for the efficacy study controlled, phase 2 trial
To assess safety, tolerability, and Phase 1/2 study of COVID‐ https://www.natur 12 August RNA Vaccine immunogenicity of RNA Nature 19 RNA vaccine Phase 1/2 trial USA/Germany Mulligan et al. e.com/articles/s41 NCT04368728 2020 BNT162b1 Vaccine candidate in a BNT162b1 in adults 586‐020‐2639‐4 dose escalation study among healthy adults.
To complement previous reported data by Concurrent human https://www.medr providing a detailed NCT04380701, antibody and TH1 type T‐ Germany/ xiv.org/content/10. RNA Vaccine characterisation of 20‐Jul‐20 Medrxiv Phase 1/2 trial Sahin et al. EudraCT: 2020‐ cell responses elicited by USA 1101/2020.07.17.2 BNT162b1 antibody and T76 cell 001038‐36 a COVID‐19 RNA vaccine 0140533v1.full.pdf immune responses elicited by BNT162b1 vaccination.
An mRNA Vaccine against https://www.nejm. To evaluate the safety and mRNA‐1273 14‐Jul NEMJ SARS‐CoV‐2 — Phase 1 trial USA Jackson et al. org/doi/pdf/10.105 NCT04283461 immunogenicity of mRNA‐ vaccine Preliminary Report 6/NEJMoa2022483 1273 vaccine
Effect of Hydroxychloroquine in To assess the safety and Hospitalized Patients Horby et al. https://www.nejm. ISRCTN efficacy of with COVID‐19: (RECOVERY Hydroxychloro 08‐Oct NEJM RCT UK org/doi/10.1056/N 50189673, hydroxychloroquine in Preliminary results from Collaborative quine NCT04381936 patients hospitalized with a multi‐centre, Group) EJMoa2022926 COVID‐19 randomized, controlled trial. A Multicenter, randomized, open‐label, controlled trial to evaluate the efficacy and https://www.medr To evaluate HCQ efficacy RCT & tolerability of Cheng‐Pin xiv.org/content/10. Hydroxychloro and tolerability in adult 10‐Jul Medrxiv retrospective Taiwan NCT04384380 hydroxychloroquine and Chen et al. 1101/2020.07.08.2 quine patients with mild to cohort study a retrospective study in 0148841v1.full.pdf moderate COVID‐19. adult patients with mild to moderate Coronavirus disease 2019 (COVID‐19)
Hydroxychloroquine in To investigate whether Annals of https://www.acpjo Nonhospitalized Adults Hydroxychloro hydroxychloroquine could 16‐Jul Internal RCT USA Skipper et al. urnals.org/doi/10.7 NCT04308668 With Early COVID‐19 ‐ A quine reduce COVID‐19 severity Medicine Randomized Trial 326/M20‐4207 in adult outpatients
Hydroxychloroquine Is early treatment with Alone or in Combination hydroxychloroquine (HCQ) https://papers.ssrn Hydroxychloro with Cobicistat‐Boosted with our without .com/sol3/papers.c quine, Preprint Lancet Darunavir for Treatment RTC Spain Mitjà et al, NCT04304053 cobicistat/darunavir more fm?abstract_id=36 Darunavir, of Mild COVID‐19: A efficacious than no‐ Cobicistat Cluster‐Randomized 15997 treatment for outpatients Clinical Trial with mild Covid‐19?
To assess the effcacy and safety of A pragmatic randomized https://assets.rese hydroxychloroquine controlled trial reports Magnus archsquare.com/fil therapy on SARS‐CoV‐2 ResearchSqua the efficacy of Nakrem es/rs‐ Hydroxychloro Preprint RCT Norway NCT04316377 oropharyngeal viral re hydroxychloroquine on Lyngbakken, 44055/v1/3fb1115 quine kinetics in patients coronavirus disease 2019 et al. 5‐d83c‐48a0‐ae74‐ hospitalized with viral kinetics b3cce9a5eac3.pdf moderately severe COVID‐ 19.
Antiviral Activity and Evaluate the antiviral Open Forum Safety of https://pubmed.nc activity and safety of Jun Chen, et Darunavir, 11 June 2020 Infectious Darunavir/Cobicistat for RCT China bi.nlm.nih.gov/326 NCT04252274 darunavir/cobicistat al. Cobicistat Diseases the Treatment of COVID‐ 71131/ (DRV/c) for treating mild 19 COVID‐19
lopinavir/riton avir; arbidol; hydroxychloro SN Systematic and Statistical https://link.springe quine; To assess the current Systematic Comprehensiv Review of Coronavirus Juan A. Siordia r.com/article/10.10 remdesivir; evidence regarding 15‐Jul‐20 review & USA N/A e Clinical Disease 19 Treatment Jr et al. 07%2Fs42399‐020‐ tocilizumab; human controlled COVID‐ Meta‐analysis Medicine Trials 00399‐6 favipiravir; 19 treatment trials. heparin; dexamethaso ne https://www.resea rchgate.net/profile /Abu_Taiub_Moha mmed_Mohiuddin _Chowdhury2/publ ication/342159343 _A_comparative_o bservational_study _on_Ivermectin‐ _Doxycycline_and_ Hydroxychloroquin Compared outcomes of Ivermectin‐Doxycycline vs. A Randomized Trial of Abu Taiub e‐ Ivermectin, Hydroxychloroquine‐ BMC Ivermectin‐Doxycycline Mohammed Azithromycin_ther Doxycycline, Azithromycin combination Preprint Infectious and Hydroxychloroquine‐ RT Bangladesh Mohiuddin apy_on_COVID19_ NCT04434144 Hydroxychloro therapy COVID19 patients Diseases Azithromycin therapy on Chowdhury, et quine, patients/links/5f02 with mild to moderate COVID19 patients. al. Azithromycin 954c92851c52d619 disease. d95e/A‐ comparative‐ observational‐ study‐on‐ Ivermectin‐ Doxycycline‐and‐ Hydroxychloroquin e‐Azithromycin‐ therapy‐on‐ COVID19‐ patients.pdf
Assess the effectiveness of Convalescent plasma or https://www.cochr Convalescent convalescent plasma and hyperimmune anelibrary.com/cds plasma, updated Systematic International Piechotta V, et hyperimmune Cochrane immunoglobulin for r/doi/10.1002/146 NA hyperimmune 12/10/20 review Collaboration al. immunoglobulin for people with COVID‐19: a immunoglobul 51858.CD013600.p treating people with living systematic review in ub2/abstract COVID19
A Randomized, Open‐ label, Controlled Clinical https://onlinelibrar Trial of Azvudine Efficacy of azvudine in Advanced Zhigang Ren, y.wiley.com/doi/ep ChiCTR200002 Preprint Tablets in the RCT China Azvudine treating mild COVID19 Science et al. df/10.1002/advs.2 9853 Treatment of Mild and patients Common COVID‐19, A 02001435 Pilot Study
Effect of Colchicine vs Standard Care on Cardiac To evaluate the effect of JAMA and Inflammatory https://jamanetwo treatment with colchicine Network Biomarkers and Clinical on cardiac and Randomized Deftereos et rk.com/journals/ja 24/06/2020 Open: Outcomes in Patients Greece NCT04326790 Colchicine inflammatory biomarkers clinical trial al. manetworkopen/f Infectious Hospitalized With and clinical outcomes in Diseases Coronavirus Disease ullarticle/2767593 patients hospitalized with 2019The GRECCO‐19 COVID‐19. Randomized Clinical Trial
The Febuxostat Therapy in International https://pubmed.nc Hydroxychloro Is febuxostat effective in Outpatients With IRCT20190727 30‐Jun‐20 Journal of RCT Iran Davoodi et al. bi.nlm.nih.gov/326 quine, comparision with Suspected COVID‐19: A 04434N1 Clinical febuxostat hydroxychloroquine? Clinical Trial 03531/ Practice https://www.nejm. org/doi/pdf/10.105 6/NEJMoa2021436 ?casa_token=H8GA Effect of Dexamethasone Horby et al. To test the effectiveness caEgprUAAAAA:m_ ISRCTN in Hospitalized Patients (RECOVERY Dexamethaso of dexamethasone in 17 July 2020 NEMJ RCT UK 9Qlb5FCP6d6YPLP 50189673, with COVID‐19: Writing ne patients hospitalized with NCT04381936 Preliminary Report Committee) MryKLqVP0QTUoui COVID‐19 QsD39ki_1j8u1syZ DvAET7pLjZ3GbCp QSV4V62JZ8086BO dT
To determine whether a 6‐ day course of intravenous GLUCOCOVID: A https://www.medr methylprednisolone (MP) controlled trial of EudraCT improves outcome in Corral‐Gudino xiv.org/content/10. methylprednis 18‐Jun medRxiv methylprednisolone in RCT Spain number: 2020‐ patients with SARS CoV‐2 et al. 1101/2020.06.17.2 olone adults hospitalized with 001934‐37 infection at risk of COVID‐19 pneumonia 0133579v1.full.pdf developing Acute Respiratory Distress Syndrome (ARDS)
Inhibition of Bruton https://immunolog Is acalabrutinib effective Science tyrosine kinase in Roschewski et y.sciencemag.org/c 05‐Jun‐20 RCT USA NA Acalabrutinib in severe COVID‐19 Immunology patients with severe al. ontent/5/48/eabd0 patients? COVID‐19 110
Were the non‐ pharmaceutical Estimating the effects of Non‐ 8 June 2020 ‐ https://www.natur interventions non‐pharmaceutical Seth Flaxman, pharmaceutic Accelerated Nature Modelling UK e.com/articles/s41 NA implemented in European interventions on COVID‐ et al. al publication countries effective in 19 in Europe 586‐020‐2405‐7 interventions limiting the spread of SARS CoV‐2?
The Janus kinase 1/2 inhibitor ruxolitinib in https://www.natur Efficacy and safety of Nature ‐ Retrospective F. La Rosée, et 8 May 2020 COVID‐19 with severe Germany e.com/articles/s41 Ruxolitinib ruxolitinib in severe Leukemia analysis al. systemic 375‐020‐0891‐0 COVID19 hyperinflammation
https://www.scien Lancet Canakinumab in a cedirect.com/scien Is canakinumab a safe and Retrospective Claudio 8 June 2020 Reheumatolog subgroup of patients Italy ce/article/pii/S266 NA Canakinumab effective treatment analysis Ucciferri, et al. y with COVID‐19 5991320301673?vi against COVID19? a%3Dihub
Use of personal protective equipment To examine the protective against coronavirus https://www.bmj.c Observational effects of appropriate 10‐Jun‐20 BMJ disease 2019 by China Min Liu et al. om/content/369/b NA NA study personal protective healthcare professionals mj.m2195 equipment in Wuhan, China: cross sectional study Effects of non‐ https://www.thela pharmaceutical ncet.com/journals/ What is the impact of interventions on COVID‐ The Lancet Modelling lanpub/article/PIIS different control 02‐Jun‐20 19 cases, deaths, and UK Gavines et al. NA NA Digital Healt study 2468‐ measures for mitigating demand for hospital the burden of COVID‐19 services in the UK: a 2667(20)30133‐ modelling study X/fulltext#%20
Clinical performance of the Luminex NxTAG CoV https://jcm.asm.or Journal of Extended Panel for SARS‐ Evaluation of Luminex Jonathan Hon‐ g/content/early/20 Nucleic acid 01‐Jun‐20 Clinical CoV‐2 detection in Diagnostic Hong‐Kong NA NxTAG in COVID‐19 Kwan Chen 20/05/29/JCM.009 test Microbiology nasopharyngeal detection specimens of COVID‐19 36‐20 patients in Hong Kong
Clinical evidence for https://www.scien Clinical repurposing chloroquine Systematic cedirect.com/scien Hydroxychloro Australia/Sri Does hydroxychloroquine 26‐May‐20 Microbiology and hydroxychloroquine review / Meta‐ Rodrigo et al. ce/article/pii/S119 NA quine, Lanka have antiviral effect? and Infection as antiviral agents: a analysis 8743X20302937?vi chloroquine systematic review a%3Dihub
Kinetics of the humoral To test the performance immune response to https://www.medr characteristics of seven SARS‐CoV‐2: comparative Herroelen et xiv.org/content/10. commercially available 14‐Jun MedRxiv Diagnostic Belgium N/A Antibody test analytical performance of al. 1101/2020.06.09.2 serology tests for seven commercial 0124719v2.full.pdf detection of antibodies serology tests against the SARS‐CoV‐2
Therapeutic https://www.medr To assess the therapeutic effectiveness of observational xiv.org/content/10. RPCEC000003 Interferon efficacy of IFN‐α2b in 09‐Jun MedRxiv interferon‐alpha 2b Cuba Pereda et al. study 1101/2020.05.29.2 18 alpha 2b patients infected with against COVID‐19: the SARS‐CoV‐2 Cuban experience 0109199v1.full.pdf
ICON (Ivermectin in To determine whether COvid Nineteen) study: https://www.medr Ivermectin is associated Use of Ivermectin is Retrospective Cepelowicz xiv.org/content/10. 10‐Jun MedRxiv USA N/A Ivermectin with lower mortality rate Associated with Lower analysis Rajter et al. 1101/2020.06.06.2 in patients hospitalized Mortality in Hospitalized 0124461v2.full.pdf with COVID‐19 Patients with COVID19
To assess the efficacy of lenzilumab therapy in First Clinical Use of prospective https://www.medr patients hospitalized with Lenzilumab to Neutralize study with severe COVID‐19 Temesgen et xiv.org/content/10. 14‐Jun MedRxiv GM‐CSF in Patients with FDA USA N/A Lenzilumab pneumonia, who had al. 1101/2020.06.08.2 Severe and Critical COVID‐ emergency clinical and/or biomarker 19 Pneumonia use IND 0125369v2.full.pdf evidence for increased risk of progression to respiratory failure. To investigate whether Low levels of the soluble urokinase prognostic biomarker https://www.medr plasminogen activator suPAR are predictive of receptor (suPAR) can aid prospective Eugen‐Olsen xiv.org/content/10. Prognostic 02‐Jun MedRxiv mild outcome in patients Denmark/USA N/A in identifying patients cohort study et al. 1101/2020.05.27.2 biomarker with symptoms of COVID‐ with low risk of 19 ‐ a prospective cohort 0114678v1.full.pdf respiratory failure when study presenting with symptoms of COVID‐19.
To determine if Low Dose‐ Low‐Dose Whole‐Lung https://www.medr Radiation Therapy can Radiation for COVID‐19 xiv.org/content/10. NCT: Low dose reduce pulmonary 08/06/2020 MedRxiv Pneumonia: Planned Day‐ CT USA Hess et al. 1101/2020.06.03.2 04366791 radiation inflammation associated 7 Interim Analysis of a with COVID‐19 Registered Clinical Trial 0116988v1.full.pdf pneumonia.
Efficacy and Safety of https://www.medr To evaluate the safety and Leflunomide for efficacy of leflunomide for xiv.org/content/10. ChiCTR200003 02‐Jun MedRxiv Refractory COVID‐19: An CT China Wang et al. Leflunomide the treatment of 1101/2020.05.29.2 0058 Open‐label Controlled refractory COVID‐19 in Study 0114223v1.full.pdf adult patients.
To explore the effect of Nano short peptide https://www.medr high fiber whey short nutrition intervention on Retrospective xiv.org/content/10. enteral 08‐Jun MedRxiv China Zhang et al. N/A peptide enteral nutrition the prognosis of patients analysis 1101/2020.06.03.2 nutrition on the prognosis of with COVID‐19 0083980v1.full.pdf patients with COVID‐19
To determine if ozonated Ozone therapy for https://www.medr autohemotherapy is patients with SARS‐COV‐ associated with a shorter prospective Spain/ Hernández et xiv.org/content/10. 05‐Jun MedRxiv 2 pneumonia: a single‐ N/A Ozone therapy time to clinical cohort study USA/Canada al. 1101/2020.06.03.2 center prospective improvement in patients cohort study 0117994v1.full.pdf with severe COVID‐19 pneumonia.
To determine the effect of CIGB‐258 Center for Genetic immunomodulatory https://www.medr CIGB‐258 Venegas‐ Engineering and peptide: a novel xiv.org/content/10. RPCEC000003 immuno‐ 02‐Jun MedRxiv CT Cuba Rodriguez et Biotechnology (CIGB)‐258 promising treatment for 1101/2020.05.27.2 13 modulatory al. therapy in seriously, or critical and severe COVID‐ peptide 0110601v1.full.pdf critically ill patients with 19 patients COVID‐19. A cohort study to To determine the clinical evaluate the effect of outcomes of older COVID‐ combination Vitamin D, https://www.medr Vitamin D, 19 patients who received Magnesium and Vitamin Observational Chuen Wen xiv.org/content/10. Magnesium 02‐Jun MedRxiv Singapore N/A Vitamin D, Magnesium B12 (DMB) on study Tan et al. 1101/2020.06.01.2 and Vitamin and Vitamin B12 (DMB) progression to severe B12 (DMB) 0112334v1.full.pdf compared to those who outcome in older COVID‐ did not 19 patients.
To evaluate differences in Therapeutic morbidity and mortality Anticoagulation Is https://www.medr among mechanically Associated with Retrospective xiv.org/content/10. anticoagulatio ventilated patients with 03‐Jun MedRxiv USA Trinh et al. N/A Decreased Mortality in analysis 1101/2020.05.30.2 n agents COVID‐19 treated with Mechanically Ventilated 0117929v1.full.pdf therapeutic versus COVID‐19 Patients prophylactic anticoagulation
https://translation EudraCT (2020‐ Tocilizumab for patients al‐ 001110‐38); To evaluate efficacy of with COVID‐19 medicine.biomedc clinicaltrials.g 21 October 202o0f Translational M CT Italy Perrone et al. Tocilizumab tocilizumab in COVID‐19 pneumonia. The TOCIVID‐ entral.com/articles ov pneumonia patients. 19 phase 2 trial /10.1186/s12967‐ (NCT0431709 020‐02573‐9 2)
To compare SAMBA II SARS‐CoV‐2 performance Rapid point of care prospective against the standard lab nucleic acid testing for https://www.medr clinical trial RTPCR test in suspected SARS‐CoV‐2 in UK/South Dami Collier, xiv.org/content/10. Nucleic acid 02/06/2020 MedRxiv and NCT04326387 COVID‐19 cases hospitalised patients: a Africa et al. 1101/2020.05.31.2 diagnostic observational presenting to hospital, clinical trial and study 0114520v1.full.pdf followed by a hospital‐ implementation study based implementation study.
To compare three fully automated large‐scale laboratory analyzer test Side by side comparison https://www.medr systems, with particular of three fully automated emphasis on specificity, Diagnostic Perkmann et xiv.org/content/10. Antibody 06‐Jun MedRxiv SARS‐CoV‐2 antibody Austria N/A which is crucial for an comparison al. 1101/2020.06.04.2 diagnostic assays with a focus on adequate positive specificity 0117911v2.full.pdf predictive value given the current low seroprevalence worldwide. To describe initial experience using a Implementation and commercially‐available evaluation of a novel real‐ https://www.medr Diagnostic multiplex two‐step nested time multiplex assay for xiv.org/content/10. Nucleic acid 05‐Jun MedRxiv validation Australia Williams et al. N/A tandem RT‐PCR assay for SARS‐CoV‐2: In‐field 1101/2020.06.03.2 diagnostic study the detection of learnings from a clinical 0117267v1.full.pdf coronaviruses that infect microbiology laboratory humans, including SARS‐ CoV‐2
To construct and validate Diagnostic for https://www.medr a cell‐free assay to Detection of SARS‐CoV‐2 Diagnostic indentifying USA/Switzerla xiv.org/content/10. measure neutralizing 02‐Jun MedRxiv neutralizing antibodies validation Danh et al. N/A suitable nd 1101/2020.05.28.2 antibodies in order to with a cell‐free PCR assay study Convalescent identify suitable donors of 0105692v1.full.pdf plasma donors convalescent plasma
To evaluate the real‐world Diagnostic accuracy of a https://www.medr diagnostic diagnostic accuracy of host response point‐of‐ xiv.org/content/10. ISRCTN149666 02‐Jun MedRxiv clinical UK Clark et al. Diagnostic FebriDx for the care test for identifying 1101/2020.05.27.2 73 evaluation identification of COVID‐19 COVID‐19 0114512v1.full.pdf in hospitalised adults
Alltest rapid lateral flow immunoassays is reliable https://www.scien To analyze the diagnostic Journal of in diagnosing SARS‐CoV‐2 cedirect.com/scien Diagnostic performance of one August 2020 Clinical infection from 14 days Spain García et al. ce/article/pii/S138 NA NA assay serologic rapid test in Virology after symptom onset: A 6653220302158?vi COVID‐19 patients prospective single‐center a%3Dihub study
Poor‐sleep is associated with slow recovery from Effects of sleep quality on lymphopenia and an https://www.scien Brain, recovery from increased need for ICU Retrospective cedirect.com/scien 06‐Jun‐20 Behaviour and China Zhang et al. NA NA lymphopenia and clinical care in hospitalized study ce/article/pii/S088 Imunity outcomes in hospitalized patients with COVID‐19: 9159120309946 patients with COVID‐19 A retrospective cohort study
To assess the overall benefit–risk of the use of Remdesivir in Treatment https://doi.org/10. remdesivir as a treatment of COVID-19: A Systematic Miranda 28 May 2020 Drug Safety UK 1007/s40264‐020‐ NA Remdesivir for COVID‐19 compared Systematic Benefit–Risk review Davies, et al. with standard of care, Assessment 00952‐1 placebo or other treatments Routine Venous To determine the Thromboembolism Venous frequency of venous Prophylaxis May Be Thomas K. DOI: Society of Observational thromboembo thromboembolism (VT) in 27 May 2020 Inadequate in the USA Maatman, et 10.1097/CCM.0000 NA Critical Care study lism critically ill COVID19 Hypercoagulable State of al. 000000004466 prophylaxis patients who recieved Severe Coronavirus prophylaxis for VT. Disease 2019
Effect of Convalescent Plasma Therapy on Time Is convalescent plasma a to Clinical Improvement doi:10.1001/jama.2 ChiCTR200002 Convalescent safe and efficient 3 June 2020 JAMA in Patients With Severe RCT China Ling Li, et al. 020.10044 9757 Plasma treatment for severe and Life‐threatening COVID19? COVID‐19 ‐ A Randomized Clinical Trial
https://www.scien Journal of the Ignacio J. cedirect.com/scien To analyze if ramipril American Ramipril in High Risk Retrospective NCT03201185 Preprint Spain Amat‐Santos, ce/article/pii/S073 Ramipril modifies the risk for College of Patients with COVID‐19 analysis (source RCT) et al. COVID‐19. Cardiology 510972035395X?vi a%3Dihub
Should health care The need of health policy workeers wear surgical perspective to protect https://journals.pl masks or N95 respirators Healthcare Workers Systematic during the routine care Primiano os.org/plosone/arti N95 3 June 2020 PlosOne during COVID‐19 review / Meta‐ Italy NA (not Iannone, et al. cle?id=10.1371/jou respirators pandemic. A GRADE analysis involving aerosol rapid review on the N95 rnal.pone.0234025 generating procedures) of respirators effectiveness COVID‐19 suspected or affected patients?
Physical distancing, face Investigate the effects of masks, and eye physical distance, face protection to prevent https://doi.org/10. PROSPERO: masks, and eye protection person‐to‐person Systematic International Derek K Chu, 1 June 2020 Lancet 1016/S0140‐ CRD42020177 PPE on virus transmission in transmission of SARS‐CoV‐ review collaboration et al. 047 health‐care and non‐ 2 and COVID‐19: a 6736(20)31183‐1 health‐care (eg, systematic review and community) settings meta‐analysis
Exposure to DPP‐4 inhibitors and COVID‐19 Diabetes, Case https://pubmed.nc Do DPP‐4 inhinbitors have among people with type Gian Paolo DPP‐4 Preprint obesity & population Italy bi.nlm.nih.gov/324 NA a protective effect agains 2 Fadini, et al. inhibitors metabolism study COVID19? diabetes. A case‐control 63179/ study
A Randomized Trial of https://www.nejm. Is hydroxychloroquine Hydroxychloroquine as D.R. Boulware, Hydroxychloro 03 June 2020 NEJM RCT USA / Canada org/doi/full/10.105 NCT04308668. effective in post‐exposure Postexposure Prophylaxis et al. quine prohylaxis therapy? for Covid‐19 6/NEJMoa2016638 Ultra‐sensitive and high‐ Can CRISPR technology Biosensors https://doi.org/10. throughput CRISPR‐ Diagnostic Zhen Huang, CRISPR RT‐ simplify RT‐PCR for SARS Preprint and USA 1016/j.bios.2020.1 NA Powered COVID‐19 assay et al. PCR CoV2 and be effective for Bioelectronics diagnosis 12316 diagnos?
Famotidine Use is Associated with https://www.gastr Improved Clinical Do COVID19 patients Daniel E. ojournal.org/article Gastroenterol Outcomes in Hospitalized Retrospective taking famotidine have a Preprint USA Freedberg, et /S0016‐ NA Famotidine ogy COVID‐19 Patients: A study lower risk of intubation al. Propensity Score 5085(20)34706‐ and/or death? Matched Retrospective 5/fulltext Cohort Study
Is a 5 day course of International Remdesivir for 5 or 10 Jason D. https://www.nejm. remedesivir as effective as collaboration/ 27 May 2020 NEJM Days in Patients with RCT Goldman, et org/doi/full/10.105 NCT04292899 Remdesivir a 10 course in treating Gilead Severe Covid‐19 al. moderately ill COVID19 Sciences 6/NEJMoa2015301 patients?
Is remdesivir an effective Remdesivir for the https://www.nejm. International J.H. Beigel, et treatment for reducing 22 May 2020 NEJM Treatment of Covid‐19 — RCT org/doi/full/10.105 NCT04280705 Remdesivir collaboration al. time to recovery in Preliminary Report 6/NEJMoa2007764 COVID19 patients?
Ruxolitinib in treatment Journal of of severe coronavirus https://doi.org/10. To evaluate the efficacy Allergy and disease 2019 (COVID‐19): Yang Cao, et ChiCTR‐OPN‐ and safety of ruxolitinib Preprint RCT China 1016/j.jaci.2020.05 Ruxolitinib Clinical A multicenter, single‐ al. 2000029580. for patients with severe Immunology blind, randomized .019 COVID19. controlled trial
Thymosin alpha 1 (Tα1) reduces the mortality of Clinical severe COVID 19 by https://pubmed.nc Is thymosin alpha a safe Retrospective Yueping Liu, et Thymosin Preprint Infectious restoration of China bi.nlm.nih.gov/324 NA and effective treatment study al. alpha Diseases lymphocytopenia and 42287/ for severe COVID19? reversion of exhausted T cells
HUMAN CORONAVIRUS International https://www.scien Level of protection DATA FROM FOUR C Raina Journal of cedirect.com/scien confered by masks and Preprint CLINICAL TRIALS OF Review Australia MacIntyre, et NA PPE Infectious ce/article/pii/S120 respirators for common MASKS AND al. Diseases coronavirus. RESPIRATORS 1971220303994
https://www.thela Use of anakinra in Anakinra for severe ncet.com/journals/ The Lancet patients who were 29‐May‐20 forms of COVID‐19: a Cohort study France Huet et al. lanrhe/article/PIIS2 NA Anakinra Rheumatology admitted to hospital for cohort study 665‐9913(20)30164‐ severe forms of COVID‐19 8/fulltext Safety, tolerability, and immunogenicity of a https://www.thela recombinant adenovirus Are different doses of Ad5 ncet.com/journals/ Ad5 vectored type‐5 vectored COVID‐ Feng‐Cai Zhu vectored COVID‐19 22‐May‐20 The Lancet CT China lancet/article/PIIS0 NCT04313127 COVID‐19 19 vaccine: a dose‐ et al. vaccine safe and vaccine escalation, open‐label, 140‐6736(20)31208‐ immunogenic? non‐randomised, first‐in‐ 3/fulltext human trial
A comparative study on the time to achieve negative nucleic acid https://www.resea Antiviral effect of Danopevir and testing and hospital stays Comparative Zhicheng rchsquare.com/arti danopevir or 29‐May‐20 Preprint China NA lopinavir/riton between Danoprevir and study Zhang et al. cle/rs‐ lopinavir/ritonavir in avir Lopinavir/Ritonavir in the 28376/v1.pdf COVID‐19 patients treatment of patients with COVID‐19
Potential of Arbidol for Post‐exposure https://link.springe Current Prophylaxis of COVID‐19 Observational r.com/content/pdf Is Arbidol effective in 01‐Jun‐20 Medical Transmission–A China Zhang et al. NA Arbidol study /10.1007/s11596‐ profylaxis of COVID? Science Preliminary Report of a Retrospective Cohort 020‐2203‐3.pdf Study
Interferon beta‐1a as a Advanced http://ajem.tums.a Candidate for COVID‐19 Is interferon beta1a Journal of Payandemehr c.ir/index.php/aje IRCT20150914 Interferon 26‐May‐20 Treatment; An Open‐ CT Iran effective in treatment of Emergency et al. m/article/view/454 024017N1 beta1a label Single‐Arm Clinical COVID‐19? Medicine Trial /307
Efficacy and safety of https://aac.asm.or To evaluate efficacy and interferon beta‐1a in Davoudi‐ Antiviral g/content/early/20 IRCT20100228 Interferon safety of IFN β‐1a in 13 July 2020 treatment of severe RCT Iran Monfared et Agents 20/07/08/AAC.010 003449N28 beta‐1a patients with severe COVID‐19: A randomized al. COVID‐19. clinical trial 61‐20
A serological assay to https://www.medr To develop and clinically detect SARS‐CoV‐2 Clinical evaluate an at‐home xiv.org/content/10. IRB protocol Antibody 30/05/2020 medRxiv antibodies in at‐home Evaluation of USA Karp et al. finger‐prick dried blood 1101/2020.05.29.2 #20180015 diagnostic test collected fingerprick diagnostic test spot test to detect SARS‐ dried blood spots 0116004v2.full.pdf CoV‐2 antibodies
Performance evaluation https://www.medr To assess the analytical of the point‐of‐care Clinical xiv.org/content/10. and clinical performance UK/USA/South Assennato et Nucleic acid 27/05/2020 medRxiv SAMBA II SARS‐CoV‐2 Evaluation of 1101/2020.05.24.2 N/A of the SAMBA II 83 SARS‐ Africa al. diagnostic test Test for detection of diagnostic test 0100990v2.article‐ CoV‐2 Test using panels SARS‐CoV‐2 info and clinical samples. https://www.medr To develop and clincally EasyCOV : LAMP based Clinical saliva evaluate a new simple L’Helgouach xiv.org/content/10. 30/05/2020 medRxiv rapid detection of SARS‐ Evaluation of France N/A RT‐LAMP saliva SARS‐CoV‐2 et al. 1101/2020.05.30.2 CoV‐2 in saliva diagnostic test diagnostic test detection test based on 0117291v1.full.pdf RT‐LAMP technology
To evaluate the Evaluation of https://www.medr performance of two performance of two SARS‐ Clinical Antibody xiv.org/content/10. COVID 19 IgM/IgG Rapid 27/05/2020 medRxiv CoV‐2 Rapid whole‐blood Evaluation of France Prazuck et al. N/A rapid 1101/2020.05.27.2 Diagnostic Tests finger‐stick IgM‐IgG diagnostic test diagnostic test compared to the gold Combined Antibody Tests 0112888v1.full.pdf standard, RT‐PCR.
Mortality reduction in 46 To show the potential severe Covid‐19 patients https://www.medr efficacy and safety of treated with hyperimmune plasma proof of xiv.org/content/10. convalescent 29/05/2020 medRxiv hyperimmune plasma. A Italy Perotti et al. NCT 04321421 infusions, obtained from concept study 1101/2020.05.26.2 plasma proof of concept single convalescent donors, in arm multicenter 0113373v1.full.pdf COVID‐19 patients with interventional trial respiratory failure
To analyse the outcomes Use of High Flow Nasal https://www.medr of COVID‐19 patients with Therapy to Treat Retrospective xiv.org/content/10. High Flow moderate‐to‐severe 26/05/2020 medRxiv Moderate to Severe USA Patel et al. analysis 1101/2020.05.22.2 Nasal Therapy hypoxemic respiratory Hypoxemic Respiratory failure receiving High Flow Failure in COVID‐19 0109355v1.full.pdf Nasal Therapy
Hydroxychloroquine or chloroquine with or https://www.thela without a with or without ncet.com/journals/ Are these treatment Observational USA/Switzerla Hydroxychloro 22‐May‐20 The Lancet a macrolide for Mehra et al. lancet/article/PIIS0 NA regimens associated with study nd quine treatment of COVID‐19: a 140‐6736(20)31180‐ in‐hospital death? multinational registry 6/fulltext analysis
https://www.fronti Is Interferon‐a2b efficient Frontiers in Interferon‐a2b Qiong Zhou, et ersin.org/articles/1 in accelerating viral 15 May 2020 CT Canada, China NA Interferon‐a2b Immunology Treatment for COVID‐19 al. 0.3389/fimmu.202 clearance and reducing 0.01061/full inflammation markers?
To examine the role of Early Short Course https://www.medr Clinical early corticosteroid Corticosteroids in Retrospective xiv.org/content/10. corticosteroid 19 May 2020 Infectious USA Fadel et al. NCT04374071 therapy in patients with Hospitalized Patients study 1101/2020.05.04.2 s Diseases moderate to severe with COVID‐19 0074609v1.full.pdf COVID‐19.
Convalescent plasma https://www.medr Is convalescent plasma an treatment of severe Sean T. H. Liu, xiv.org/content/10. Convalescent Preprint medRxiv CT USA NA effective treatment for COVID‐19: A matched et al. 1101/2020.05.20.2 plasma severe COVID19? control study 0102236v1 Use of renin–angiotensin–aldost https://www.thela renin–angiote erone system inhibitors Case ncet.com/journals/ nsin–aldoster Does use of RAAS Francisco J de 14 May 2020 Lancet and risk of COVID‐19 population Spain lancet/article/PIIS0 EUPAS34437 one system predispose patients to Abajo, et al. requiring admission to study 140‐6736(20)31030‐ inhibitors, severe COVID19? hospital: a case‐ 8/fulltext RAAS population study
To evaluate various methods of chest Resuscitation of the compressions in patients patient with with suspected/confirmed suspected/confirmed https://journals.via SARS‐CoV‐2 infection Cardiology COVID‐19 when wearing Randomized Marek Malysz, medica.pl/cardiolo Preprint Poland NA PPE conducted by medical Journal personal protective crossover trial et al. gy_journal/article/ students wearing full equipment: A view/68336 personal protective randomized multicenter equipment (PPE) for crossover simulation trial aerosol generating procedures (AGP).
Stefano Bonovas, Gerd Re‐analysis of cumulative Compassionate Use of https://www.nejm. Letters to the Fätkenheuer, incidence of 15 May 2020 NEJM Remdesivir in Covid‐19 International org/doi/full/10.105 NA Remdesivir editor Christian improvement, patient (Grein et al. ‐ NEMJ) Hoffman, 6/NEJMc2015312 classification Jiayuan Wu
https://www.clinic almicrobiologyandi To evaluate the A multiple center clinical performance of an ultra‐ Clinical Diagnostic nfection.com/actio evaluation of an ultra‐ fast single‐tube nucleic Preprint Microbiology clinical China Ji Wang, et al. n/showPdf?pii=S11 NA Diagnostic test fast single‐tube assay for acid isothermal and Infection evaluation SARS‐CoV‐2 RNA 98‐ amplification detection 743X%2820%2930 assay for SARS‐CoV‐2 RNA 284‐6
A combined Are combined oropharyngeal/nares oropharyngeal/nares https://www.scien Oropharyngea Journal of swab is a suitable Diagnostic swab is a suitable cedirect.com/scien l/nares and Preprint Clinical alternative to assay Canada Jason J., et al. NA alternative for ce/article/pii/S138 nasopharynge Virology nasopharyngeal swabs comparison nasopharyngeal swabs for al swabs for the detection of SARS‐ 6653220301840 COVID19 sample CoV‐2 colleciton?
Can an AI model rapidly identify SARS‐CoV‐2 Artificial https://www.natur infection based on initial intelligence–enabled Diagnostic Xueyan Mei, AI diagnostic chest CT scans and 19 May 2020 Nature Chinq e.com/articles/s41 N/A rapid diagnosis of assay et al. algorithm associated clinical patients with COVID‐19 591‐020‐0931‐3 information of COVID‐19 (+) patients in the early stage? dipeptidyl To investigate the effects Effects of a DPP‐4 peptidase‐4 of dipeptidyl peptidase‐4 inhibitor and RAS https://www.medr (DPP‐4i), (DPP‐4i) and blockade on clinical retrospective Sang Youl xiv.org/content/10. 23‐May Medrxiv South Korea N/A renin–angiote renin–angiotensin system outcomes of patients analysis Rhee et al. 1101/2020.05.20.2 nsin system (RAS) blockade on the with diabetes and COVID‐ 0108555v1.full.pdf (RAS) short‐term clinical 19 blockade outcomes of COVID‐19
Do COVID‐19 patients To investigate the https://www.medr anti‐ admitted to the ICU prevalence of prospective xiv.org/content/10. Pneumocystis 22‐May Medrxiv require anti‐ France Alanio N/A Pneumocystis jirovecii in cohort study 1101/2020.05.18.2 jirovecii Pneumocystis jirovecii COVID‐19 patients prophylaxis prophylaxis? 0105296v1.full.pdf admitted to the ICU
Development and clinical To develop and validate a application of a rapid and https://www.medr novel RT‐LAMP assay sensitive loop‐mediated xiv.org/content/10. RT‐LAMP capable of detecting SARS‐ 23/05/2020 Medrxiv Diagnostic China Hu et al. N/A isothermal amplification 1101/2020.05.20.2 Diagnostic test CoV‐2 RNA for potential test for SARS‐CoV‐2 0108530v2 use in centralized facilities infection and point‐of‐care settings
Use of siltuximab in https://www.medr Efficacy of siltuximab for patients with COVID‐19 retrospective xiv.org/content/10. 22 May 2020 Medrxiv Italy, UK Gritti et al. NCT04322188 siltuximab treatment of severe pneumonia requiring analysis 1101/2020.04.01.2 patients with COVID‐19 ventilatory support 0048561v3.full.pdf
Almitrine as a non https://www.medr To test if intravenous ventilatory strategy to almitrine can improve Case control xiv.org/content/10. 22‐May Medrxiv improve intrapulmonary France Losser et al. N/A Almitrine hypoxia in mechanically series 1101/2020.05.18.2 shunt in COVID‐19 ventilated COVID‐19 patients 0105502v1.full.pdf patients.
To examine the benefit‐ Remdesivir in treatment https://www.medr risk profile of remdesivir Systematic of COVID‐19: A xiv.org/content/10. in COVID‐19 patients 12‐May MedRxiv benefit‐risk UK Davies et al. N/A Remdesivir systematic benefit‐risk 1101/2020.05.07.2 compared to standard assessment assessment 0093898v1.full.pdf of care, placebo or other treatments.
Assisting Scalable Application of https://www.medr To test the hypothesis Diagnosis Automatically deep learning that application of deep xiv.org/content/10. 15‐May MedRxiv via CT Images in the to China Liu et al. N/A Chest CT learning to 3D chest CT 1101/2020.05.11.2 Combat against COVID‐ retrospective images could help identify 19 analysis 0093732v1.full.pdf COVID‐19 infections. The effects of ARBs, To explore the association ACEIs and statins on https://www.medr of ACEi/ARB and/or clinical outcomes of retrospective De Spiegeleer xiv.org/content/10. ARBs, ACEi, statins with clinical 15‐May MedRxiv Belgium N/A COVID‐19 infection analysis et al. 1101/2020.05.11.2 Statins manifestations in COVID‐ among nursing home 0096347v1.full.pdf 19 infected older people residents residing in nursing homes.
To analyse key safety https://www.medr metrics following Early Safety Indicators of expanded xiv.org/content/10. Convalescent transfusion of 14‐May MedRxiv COVID‐19 Convalescent access USA Joyner et al. NCT04338360 1101/2020.05.12.2 plasma convalescent plasma in Plasma in 5,000 Patients program 0099879v1.full.pdf patients with severe or life‐ threatening COVID‐19
To report the clinical Nebulized in‐line course, safety, and endotracheal dornase https://www.medr Nebulized in‐ outcomes after nebulized alfa and albuterol retrospective xiv.org/content/10. NCT0438778 line in‐line endotracheal 15‐May MedRxiv administered to USA Weber et al. case study 1101/2020.05.13.2 6 endotracheal dornase alfa treatment for mechanically ventilated Dornase Alfa intubated and COVID‐19 patients: A 0087734v1.full.pdf mechanically ventilated case series patients with COVID‐19.
To determine if Treatment of COVID‐19 https://www.medr transfusion of Patients with xiv.org/content/10. Convalescent convalescent plasma is a 13‐May MedRxiv Case series USA Salazar et al. N/A Convalescent Plasma in 1101/2020.05.08.2 plasma safe treatment option for Houston, Texas 0095471v1.full.pdf those with severe COVID‐ 19 disease.
http://viruseradica tion.com/journal‐ details/A_review_o A review of the safety of Journal of Victoria f_the_safety_of_fa favipiravir – a potential Systematic 30 April 2020 Virus UK Pilkington, et vipiravir_%E2%80% NA Favipiravir Safety of favipiravir treatment in the COVID‐ review Eradication al. 19 pandemic? 93_a_potential_tre atment_in_the_CO VID‐ 19_pandemic%5E/
To evaluate the safety and Allogeneic impact of administration cardiosphere-derived https://link.springe of allogeneic CDCs, cells (CAP-1002) in Basic Research Siddharth r.com/article/10.10 formulated for 12 May 2020 critically ill Case series USA NA CAP‐1002 in Cardiology Singh, et al. 07/s00395‐020‐ intravenous (IV) COVID-19 patients: infusion as CAP‐1002, in compassionate-use case 0795‐1 critically ill COVID‐19 series patients. Efficacy and safety of corticosteroids in COVID‐ 19 based on evidence for Canadian COVID‐19, other https://www.cmaj. Assess efficacy and safety Systematic Medical coronavirus infections, International Zhikang Ye, et ca/content/cmaj/e Corticosteroid of corticosteroids for Preprint Review ; Meta‐ NA Association influenza, community‐ Collaboration al. arly/2020/05/14/c s COVID19, SARS, MERS, analysis Journal acquired pneumonia and maj.200645.full.pdf CAP, ARDS and influenza acute respiratory distress syndrome: a systematic review and meta‐analysis
Pilot prospective open, Clinical and single‐arm multicentre https://www.clinex To assess the efficacy and S. Sciascia, et 1 May 2020 Experimental study on off‐label use of CT Italy prheumatol.org/ab NA Tocilizumab safety of tocilizumab in al. Rheumatology tocilizumab in patients stract.asp?a=15723 severe COVID19 patients with severe COVID‐19
Facial protection for https://gh.bmj.co Efficacy of different facial BMJ Global healthcare workers Scoping Laura R Garcia Facial protection devices, 23 April 2020 USA m/content/5/5/e0 NA Health during pandemics: a Review Godoy, et al. protection especially in light of N95 scoping review 02553 respirator shortages
Compassionate remdesivir treatment of severe Covid‐19 pneumonia in intensive https://pubmed.nc Comparative efficacy of Pharmacologic Spinello Preprint care unit (ICU) and Non‐ Case series Italy bi.nlm.nih.gov/324 NA Remdesivir remdesivir in ICU and non‐ al Research Antinori, et al. ICU patients: Clinical 07959/ ICU patients outcome and differences in post treatment hospitalisation status
To evaluate which type of Personal protective full‐body PPE and which equipment for https://www.cochr method of donning or preventing highly anelibrary.com/cds do.ing PPE have the least Cochrane infectious diseases due Systematic International Verbeek JH, et 15 April 2020 r/doi/10.1002/146 NA PPE risk of contamination or Library to exposure to Review Collaboration al. infection for HCW, and contaminated body fluids 51858.CD011621.p which training methods in healthcare ub4/full increase compliance with staff PPE protocols. To assess whether Convalescent plasma or https://www.cochr convalescent plasma or hyperimmune anelibrary.com/cds hyperimmune Cochrane Systematic Convalescent 14 May 2020 immunoglobulin for Netherlands Valk SJ, et al. r/doi/10.1002/146 NA immunoglobulin Library Review Plasma people with COVID‐19: a 51858.CD013600/f transfusion is eJective and rapid review ull safe in the treatment of people with COVID‐19.
Preliminary assessment of Journal of Safety and efficacy of https://www.jacio the safety and efficacy of Allergy and early high‐dose IV Emanuele nline.org/article/S0 Preprint Case series Italy NA Anakinra anakirna in Clinical anakinra in severe COVID‐ Pontali, et al. 091‐6749(20)30634‐ severe/moderate Immunology 19 lung disease 5/fulltext COVID19
Tocilizumab for Treatment of Severe https://pubmed.nc What is the role of Microorganis COVID‐19 Patients: Observational tocilizumab therapy in 09 May 2020 Italy Colaneri et al. bi.nlm.nih.gov/323 NA tocilizumab ms Preliminary Results From study severe COVID‐19 SMAtteo COvid19 97399/ patients? REgistry (SMACORE)
Hydroxychloroquine in Patients With Mainly Mild to Moderate https://www.bmj.c Is hydroxychloroquine ChiCTR200002 Hydroxychloro 14 May 2020 BMJ Coronavirus Disease RCT China Tang et al. om/content/369/b effective and safe in 9868 quine 2019: Open Label, mj.m1849.long COVID‐19 patients? Randomised Controlled Trial
Clinical efficacy of hydroxychloroquine in patients with covid‐19 https://www.bmj.c Observational Hydroxychloro Is hydroxychloroquine 05 May 2020 BMJ pneumonia who require France Mahévas et al. om/content/369/b NA study quine effective? oxygen: observational mj.m1844 comparative study using routine care data
To assess and compare the performance of 6 Detection of SARS‐CoV‐2 https://www.medr rapid tests and 3 ELISAs antibodies using Clinical xiv.org/content/10. Antibody for the diagnosis of COVID‐ 08 May 2020 MedRxiv commercial assays and Evaluation of France Tuaillon et al. NCT04347850 1101/2020.05.04.2 diagnostic test 19, and to explore seroconversion patterns diagnostic test seroconversions in in hospitalized patients 0090027v3.full.pdf subjects with confirmed COVID‐19
ddPCR: a more sensitive https://www.medr To compare the dynamic Clinical and accurate tool for xiv.org/content/10. PCR diagnostic range and the limit of 08 May 2020 MedRxiv evaluation of China Suo et al. SARS‐CoV‐2 detection in 1101/2020.02.29.2 test detection (LoD) between diagnostic test low viral load specimens 0029439v2.full.pdf ddPCR and RT‐PCR Clinical Outcomes and To evaluate the efficacy Plasma Concentrations of https://www.medr and safety of adding Baloxavir Marboxil and baloxavir xiv.org/content/10. ChiCTR200002 baloxavir marboxil or 05 May 2020 MedRxiv Favipiravir in COVID‐19 RCT China Yan Lou et al. marboxil, 1101/2020.04.29.2 9544 favipiravir to the current Patients: an Exploratory favipiravir standard antiviral Randomized, Controlled 0085761v1.full.pdf treatment Trial
https://www.medr To determine if excessive Celebrex adjuvant PGE2 may be a key in the Wenxin Hong xiv.org/content/10. ChiCTR200003 Celebrex 11 May 2020 MedRxiv therapy on COVID‐19: An Clinical trial China pathology of COVID‐19 et al. 1101/2020.05.05.2 1630 (Celecoxib) experimental study and whether COX‐2 is a 0077610v1.full.pdf critical target for therapy.
To take into account the possible confounders retrospective https://www.medr when analyzing the COVID‐19 Related analysis of xiv.org/content/10. difference in mortality 05 May 2020 MedRxiv Mortality: Is the BCG Mexico Paredes et al. N/A BCG International 1101/2020.05.01.2 rates between countries Vaccine Truly Effective? mortality rates 0087411v1.full.pdf with and without history of a universal BCG vaccination program.
Hydroxychloroquine and zinc sulfate (as To determine if zinc azithromycin plus zinc vs https://www.medr add‐on sulfate added to retrospective hydroxychloroquine and xiv.org/content/10. therapy to hydroxychloroquine and 08 May 2020 MedRxiv observational USA Carlucci et al. N/A azithromycin alone: 1101/2020.05.02.2 hydroxychloro azithromycin may improve study outcomes in hospitalized 0080036v1.full.pdf quine and outcomes among COVID‐19 patients azithromycin) hospitalized patients.
To evaluate the Efficacy of face mask in https://www.medr effectiveness of the use of preventing respiratory Systematic xiv.org/content/10. masks to prevent 05 May 2020 MedRxiv virus transmission: a review and China Liang et al. N/A facemask 1101/2020.04.03.2 laboratory‐confirmed systematic review and meta‐analysis respiratory virus meta‐analysis 0051649v3.full.pdf transmission.
Impact of corticosteroid therapy on outcomes of https://www.natur Evaluate the safety and persons with SARS‐CoV‐ e.com/articles/s41 Corticosteroid efficacy of corticosteroids 5 May 2020 Nature 2, SARS‐CoV, or MERS‐ Meta‐analyisis China Huan Li, et al. NA 375‐020‐0848‐ s on SARS‐CoV‐2, SARS‐CoV, CoV infection: a and MERS‐CoV infections systematic review and 3.pdf meta‐analysis
Journal of In Silico Trial to test https://www.biorxi Can an efficient in‐silico Biomedical COVID‐19 candidate Giulia Russo, Giulia Russo, v.org/content/10.1 trial base be developed, Preprint Italy NA Vaccine and Health vaccines: a case study et al. et al. 101/2020.05.06.08 and can it evaluate Informatics with UISS platform 0630v1.full.pdf vaccine candidates? Were non‐pharmaceutical Effect of non‐ https://www.natur Non‐ interventions effective in pharmaceutical Mathematical Shengjie Lai, e.com/articles/s41 pharmaceutic reducing the number of Preprint Nature interventions to contain China, UK, US NA Modeling et al. 586‐020‐2293‐ al cases and speed of the COVID‐19 in China x_reference.pdf interventions epidemic in mainland China?
Continuous hydroxychloroquine or https://www.ncbi. Protective role of colchicine therapy does Omer Colchicine, Autoimmunity Retrospective nlm.nih.gov/pmc/a colchicine or 29 April 2020 not prevent infection Israel Gendelman, NA hydroxychloro Reviews analysis rticles/PMC719840 hydroxychloriquine for with SARS‐CoV‐2: Insights et al. quine COVID19 infection from a large healthcare 6/ database analysis
Tocilizumab for the treatment of severe COVID‐19 pneumonia https://www.scien Is tocilizumab effective for with hyperinflammatory cedirect.com/scien Autoimmunity Observational Paola Toniati, improving respiratory Preprint syndrome and acute Italy ce/article/abs/pii/S NA Tocilizumab Reviews study et al. condition in severe respiratory failure: A 156899722030130 COVID19? single center study of 0 100 patients in Brescia, Italy
https://www.pnas. Effective treatment of org/content/pnas/ Efficacy and safety of Retrospective Xiaoling Xua, April 29 2020 PNAS severe COVID‐19 patients China early/2020/04/27/ Tocilizumab tocilizumab in sever analysis et al. with tocilizumab 2005615117.full.pd COVID19 f
Triple combination of interferon beta‐1b, https://www.thela lopinavir–ritonavir, and ncet.com/journals/ interferon ribavirin in the treatment beta‐1b, The efficacy and safety of 08 May 2020 The Lancet RCT Hong Kong Hung et al. lancet/article/PIIS0 NCT04276688 of patients admitted to lopinavir–rito combination hospital with COVID‐19: 140‐6736(20)31042‐ navir, ribavirin an open‐label, 4/fulltext randomised, phase 2 trial
Interleukin‐1 blockade with high‐dose anakinra https://www.thela in patients with COVID‐ ncet.com/journals/ The Lancet 19, acute respiratory Observational 07 May 2020 Italy Cavalli et al. lanrhe/article/PIIS2 NCT04318366 anakinra Efficacy of anakinra Rheumatology distress syndrome, and study hyperinflammation: a 665‐9913(20)30127‐ retrospective cohort 2/fulltext study
https://www.scien Supportive Treatment Journal of cedirect.com/scien Outcomes associated with with Tocilizumab for Systematic 19 April 2020 Clinical USA Alzghari et al. ce/article/pii/S138 NA NA TCZ treatment in patients COVID‐19: A Systematic Review Virology with COVID‐19 Review 6653220301220?vi a%3Dihub Umifenovir treatment is https://www.clinic not associated with almicrobiologyandi Effectiveness and safety of improved outcomes in Retrospective nfection.com/articl Umifenovir 25 April 2020 icrobiology and China N. Lian, et al. NA umifenovir for moderate patients with coronavirus CT e/S1198‐ (Arbidol) COVID‐19 disease 2019: A 743X(20)30234‐ retrospective study 2/fulltext
Is Baricitinib an effective Baricitinib therapy in https://www.ncbi. drug for clinical and COVID‐19: A pilot study Fabrizio nlm.nih.gov/pmc/a 16 April 2020 urnal of Infectio CT Italy NA Baricitinib respiratory improvement on safety and clinical Cantini, et al. rticles/PMC717707 in moderate COVID19 impact 3/ patients?
Mandated Bacillus https://www.medr Calmette‐Guérin (BCG) Does BCG vaccination growth curve xiv.org/content/10. BCG 04 May 2020 medRxiv vaccination predicts USA Berg et al. N/A serve as a protective analysis 1101/2020.04.05.2 vaccination flattened curves for the factor against COVID‐19 spread of COVID‐19 0054163v5.full.pdf
Does TB Vaccination regression https://www.medr To assess the Reduce COVID‐19 analysis based xiv.org/content/10. BCG effectiveness of BCG 22 April 2020 medRxiv Infection? No Evidence on USA/ Japan Fukui et al. N/A 1101/2020.04.13.2 vaccination vaccination against COVID‐ from a Regression observational 19 Discontinuity Analysis data 0064287v1.full.pdf
A Novel Protein Drug, https://www.medr Novaferon, To determine the antiviral Novaferon, as the Fang Zheng et xiv.org/content/10. ChiCTR200002 29 April 2020 medRxiv RCT China Lopinavir/Rito effects of Novaferon for Potential Antiviral Drug al. 1101/2020.04.24.2 9496 navir COVID‐19 for COVID‐19 0077735v1.full.pdf
Review and To summarise the data on methodological analysis all currently tested all treatment of trials currently testing https://www.medr treatment and prevention and treatment and Systematic Greece, xiv.org/content/10. options for COVID‐19, and 01 May 2020 medRxiv Fragkou et al. N/A preparation prevention options for review France 1101/2020.04.27.2 to methodologically options for the novel coronavirus analyse and evaluate the 0080226v1.full.pdf covid‐19 disease (COVID‐19) quality of the registered globally. interventional studies
Hydroxychloroquine https://www.medr Could hydroxychloroquine application is associated administration be retrospective xiv.org/content/10. Hydroxychloro 01 May 2020 medRxiv with a decreased China Bo Yu et al. N/A beneficial in the analysis 1101/2020.04.27.2 quine mortality in critically ill treatment of critically ill patients with COVID‐19 0073379v1.full.pdf patients with COVID‐19?
To determine if anti‐ Hypertension and Renin‐ https://www.medr anti‐ hypertensive drugs are Angiotensin‐Aldosterone retrospective xiv.org/content/10. 29 April 2020 medRxiv USA Ip et al. N/A hypertensive harmful or beneficial to System Inhibitors in analysis 1101/2020.04.24.2 agents Covid‐19 patients with Patients with Covid‐19 0077388v1.full.pdf hypertension To evaluate the antiviral Lopinavir‐ritonavir alone efficacy of or combined with arbidol https://www.medr lopinavir/ritonavir alone in the treatment of 73 retrospective xiv.org/content/10. lopinavir/riton 29 April 2020 medRxiv China Xiu Lan et al. N/A or combined with arbidol hospitalized patients analysis 1101/2020.04.25.2 avir, arbidol in the treatment of with COVID‐19: a pilot 0079079v1.full.pdf hospitalized patients with retrospective study COVID‐19.
Preliminary evidence from a multicenter https://www.medr To assess the efficacy and prospective prospective Mingxing xiv.org/content/10. safety of chloroquine with 04 May 2020 medRxiv observational study of observational China hiCTR20000296 Chloroquine Huang et al. 1101/2020.04.26.2 different doses in COVID‐ the safety and efficacy of study 19 chloroquine for the 0081059v1.full.pdf treatment of COVID‐19
To evaluate the effects of QT Interval Prolongation Hydroxychloroquine/Azith and Torsade De Pointes https://www.medr Hydroxychloro romycin on the QT in Patients with COVID‐ retrospective xiv.org/content/10. 01 May 2020 medRxiv USA/Italy Chorin et al. N/A quine, interval and the 19 treated with analysis 1101/2020.04.27.2 Azithromycin arrhythmic risk in patients Hydroxychloroquine/Azit 0074583v1.full.pdf with SARS‐CoV‐2 hromycin infection.
To assess and compare all Performance & Quality https://www.medr nucleic acid‐based COVID‐ Evaluation of Marketed diagnostic kit David Surace xiv.org/content/10. qPCR 01 May 2020 medRxiv China N/A 19 testing kits from COVID‐19 RNA Detection evaluation Kapitula et al. 1101/2020.04.25.2 Diagnostic test quality control Kits 0080002v1.full.pdf perspectives
azithromycin, To determine the relative Risk of drug‐induced chloroquine, risk of drug‐induced Long Long QT Syndrome https://www.medr favipiravir, QT Syndrome (LQTS) associated with the use Systematic xiv.org/content/10. hydroxychloro associated with SARS‐CoV‐ 29 April 2020 medRxiv USA/Canada Michaud et al. N/A of repurposed COVID‐19 review 1101/2020.04.21.2 quine, 2 (COVID‐19) proposed drugs: a systematic 0066761v2.full.pdf lopinavir/riton repurposed drugs review avir, compared to well‐known remdesivir torsadogenic compounds
retrospective analysis, To evaluate the risk of Bayesian https://www.medr Concentration‐ overdose for chloroquine logostic Thailand/ UK/ xiv.org/content/10. 29 April 2020 medRxiv dependent mortality of Watson et al. N/A Chloroquine treatment or prevention regression, France 1101/2020.04.24.2 chloroquine in overdose regimens currently being pharmacodyn 0078303v1.full.pdf trialled in COVID19 amic modelling
Remdesivir in adults with https://www.thela severe COVID‐19: a ncet.com/journals/ randomised, double‐ Effect of remdesivir in 29 April 2020 The Lancet RCT China Wang et al. lancet/article/PIIS0 NCT04257656 remdesivir blind, placebo‐ COVID‐19 patients controlled, multicentre 140‐6736(20)31022‐ trial 9/fulltext A Rapid Systematic https://onlinelibrar Academic Review of Clinical Trials Analyze current literature Systematic Chowdhury et y.wiley.com/doi/ab 02 May 2020 Emergency Utilizing Chloroquine and USA NA NA to find the role of CQ and review al. s/10.1111/acem.14 Medicine Hydroxychloroquine as a HCQ Treatment for COVID‐19. 005
Clinical Efficacy of Intravenous To determine the clinical https://www.medr intravenous Immunoglobulin Therapy efficacy of intravenous retrospective Ziyun Shao et xiv.org/content/10. immunoglobul 20 April 2020 medRxiv in Critical Patients with China N/A immunoglobulin (IVIG) cohort study al. 1101/2020.04.11.2 in (IVIG) COVID‐19: A Multicenter therapy in COVID‐19 therapy Retrospective Cohort 0061739v2.full.pdf patients. Study
Chloroquine dosing https://ascpt.onlin To establish best‐evidence Clin recommendations for pharmacokine to inform pediatric Verscheijden elibrary.wiley.com/ 22 April 2020 Pharmacol pediatric COVID‐ tic (PBPK) Netherlands N/A Chloroquine Chloroquine doses for et al. doi/10.1002/cpt.18 Ther. 19 supported by model children infected with modeling and simulation. 64 COVID‐19
Effect of High vs Low Doses of Chloroquine Diphosphate as To evaluate the safety & Adjunctive Therapy for https://jamanetwo efficacy of different JAMA Patients Hospitalized rk.com/journals/ja 24 April 2020 RCT Brazil Borba et al NCT04323527 Chloroquine dosages of chloroquine in Network Open With Severe Acute manetworkopen/f patients with severe Respiratory Syndrome ullarticle/2765499 COVID‐19. Coronavirus 2 (SARS‐CoV‐ 2) Infection: A Randomized Clinical Trial.
A Randomized, Single‐ blind, Group sequential, Active‐controlled Study https://www.medr To evaluate the clinical to evaluate the clinical efficacy and safety of α‐ xiv.org/content/10. ChiCTR200002 α‐Lipoic acid 21 April 2020 medRxiv efficacy and safety of α‐ RCT China Zhong et al. Lipoic acid (ALA) for 1101/2020.04.15.2 9851 (ALA) Lipoic acid for critically ill critically ill patients with patients with coronavirus 0066266v1.full.pdf COVID‐19. disease 2019（COVID‐ 19）
To systematically retrieve Effectiveness and Safety https://www.medr and summarize the of Glucocorticoids to Rapid review xiv.org/content/10. Glucocorticoid current evidence of the 22 April 2020 medRxiv Treat COVID‐19: A Rapid and meta‐ China Shuya Lu et al N/A 1101/2020.04.17.2 s effectiveness and safety of Review and Meta‐ analysis glucocorticoid therapy for Analysis 0064469v1 patients with COVID‐19 To assess the A systematic review of https://www.medr Anakinra, effectiveness of specific Anakinra, Tocilizumab, Systematic xiv.org/content/10. Tocilizumab, interleukin‐1 and ‐6 26 April 2020 MedRxiv Sarilumab and Siltuximab UK Khan et al N/A review 1101/2020.04.23.2 Sarilumab, inhibitors for the for coronavirus‐related Siltuximab treatment of coronavirus‐ infections 0076612v1.full.pdf related infections.
https://www.cytod yn.com/newsroom Southern California Preliminary /press‐ Patients Treated with results from releases/detail/415 Could leronlimab be 13 April 2020 Press release USA CytoDyn INC. NA leronlimab Leronlimab for COVID‐19 clinical trial /southern‐ effective? under Emergency IND california‐patients‐ treated‐with‐ leronlimab‐for
Transplantation of ACE2‐ Mesenchymal Stem Cells http://dx.doi.org/1 ACE2‐ Efficacy of MSC Aging and ChiCTR200002 28 February 2020 Improves the Outcome of CT China Leng et al. 0.14336/AD.2020.0 mesenchymal transplantation in COVID Disease 9990 Patients with COVID‐19 228 stem cell patients Pneumonia
https://onlinelibrar Journal of Tocilizumab treatment in What are treatment Observational y.wiley.com/doi/ful 26 March 2020 Medical COVID‐19: a single center China Luo et al. NA tocilizumab responses of TCZ in the study l/10.1002/jmv.258 Virology experience COVID‐19 patients? 01
Association of Inpatient Angiotensin‐ Use of Angiotensin converting Converting Enzyme To determine the enzyme Inhibitors and https://www.ahajo association between in‐ inhibitors Circulation Angiotensin II Receptor Observational urnals.org/doi/10.1 hospital use of ACEI/ARB 17 April 2020 China Zhang et al. NA (ACEIs) and Research Blockers with Mortality study 161/CIRCRESAHA.1 and all‐cause mortality in Angiotensin Among Patients With COVID‐19 patients with 20.317134 receptor Hypertension hypertension blockers Hospitalized With COVID‐ (ARBs) 19
Association of Renin‐ Angiotensin‐ Angiotensin System converting Inhibitors With Severity Asses the association enzyme or Risk of Death in https://jamanetwo between ACEIs/ARBs and inhibitors Patients With rk.com/journals/ja severity of illness and 23 April 2020 JAMA Case series China Juy Li, et al NA (ACEIs) and Hypertension macardiology/fulla mortality in patients with Angiotensin Hospitalized for hypertension hospitalized rticle/2765049 receptor Coronavirus Disease for COVID‐19 infection. blockers 2019 (COVID‐19) (ARBs) Infection inWuhan, China
Potential therapeutic https://www.scien Is treatment with Acta effects of dipyridamole in Xiaoyan Liu, et cedirect.com/scien dipyridamol clinically PrePrint Pharmaceutic RCT China NA Dipyridamole the severely ill patients al. ce/article/pii/S221 effetive in severly ill a Sinica B with COVID‐19 1383520305529 COVID19 patients? Benefits and Risks of Chloroquine and Hydroxychloroquine in https://www.medr chloroquine/h To evaluate the efficacy The Treatment of Viral meta‐analysis Jing Wang et xiv.org/content/10. 18 April 2020 medRxiv China/ USA ydroxychoroq and safety of Chloroquine Diseases: A Meta‐ of RCTs al 1101/2020.04.13.2 uine and hydroxychloroquine Analysis of Placebo 0064295v1.full.pdf Randomized Controlled Trials
Physical interventions to To assess the interrupt or reduce the effectiveness of hand spread of respiratory https://www.medr hygiene, surface systematic Saudi Arabia, viruses. Part 2 ‐ Hand xiv.org/content/10. hygiene disinfecting, and other 20 April 2020 medRxiv review and Australia, Al‐Ansary NA hygiene and other 1101/2020.04.14.2 interventions hygiene interventions in meta‐analysis Canada hygiene measures: 0065250v1.full.pdf preventing or reducing systematic review and the spread of illnesses meta‐analysis. from respiratory viruses
An experimental trial of To investigate the efficacy recombinant human Recombinant https://www.medr and safety of recombinant interferon alpha nasal human xiv.org/content/10. human interferon alpha1b 17 April 2020 medRxiv drops to prevent Clinical trial China Meng et al. NCT04320238 interferon‐ 1101/2020.04.11.2 (rhIFN‐α) nasal drops in coronavirus disease 2019 alpha nasal healthy medical staff to in medical staff in an 0061473v1.full.pdf drops prevent COVID‐19. epidemic area
An exploratory randomized, controlled study on the efficacy and safety of https://www.medr Lopinavir‐Ritonavir 23 March lopinavir/riton lopinavir/ritonavir or xiv.org/content/10. combination compared to 2020, updated medRxiv RCT China Li et al. NCT04252885 avir (Kaletra), arbidol treating adult 1101/2020.03.19.2 Arbidol compared to no 15 April 2020 arbidol patients hospitalized 0038984v2.full.pdf antiviral treatment with mild/moderate COVID‐19 (ELACOI)
Potential Effectiveness and Safety of Antiviral https://www.medr To assess the potential Agents in Children with review and xiv.org/content/10. effectiveness and safety of 17 April 2020 medRxiv China Shi et al. NA antivirals Coronavirus Disease meta‐analysis 1101/2020.04.13.2 antiviral agents for COVID‐ 2019: A Rapid Review 0064436v1.full.pdf 19 in children. and Meta‐Analysis
The aim of this review was Efficacy and Safety of https://www.medr to evaluate the efficacy Antibiotic Agents in xiv.org/content/10. 17 April 2020 medRxiv rapid review China Wang et al NA antibiotics and safety of antibiotic Children with COVID‐19: 1101/2020.04.13.2 agents in children with A Rapid Review 0064402v1.full.pdf COVID‐19 No evidence of rapid antiviral clearance or https://www.scien Is hydroxychloroquine clinical ben‐efit with the Médécine et Prospective cedirect.com/scien Hydroxychloro effecitve for viral combination of JM Molina et Preprint Maladies virological France ce/article/pii/S039 NA quine, clearance when hydroxychloroquine and al. Infectieuses assay azithromycin reproducing the study of azithromycin in patients 9077X20300858?vi Gautrel et al.? with severe COVID‐19 a%3Dihub infection
Grant from the National Natural Science Foundation of The effect of https://www.scien China (Jing corticosteroid treatment cedirect.com/scien Liu, grant no. Evaluate the influence of Accepted 31 Journal of on patients with Zhenwei Yang, Corticosteroid Meta‐analysis China ce/article/pii/S016 81472735 ) corticosteroids in patients March 2020 Infection coronavirus infection: a et al. s and the with coronavirus. systematic review and 3445320301912?vi Wuhan meta‐analysis a%3Dihub University (Jing Liu, grant no. 2042019kf020 6
Towards Optimization of https://academic.o Clinical What is the best dose of Hydroxychloroquine Prospective PK Sophie Perinel up.com/cid/article/ Hydroxychloro Preprint Infectious France NA hydroxychloroquine for Dosing in Intensive Care study et al, doi/10.1093/cid/ci quine Diseases COVID19 patients? Unit COVID‐19 Patients aa394/5816960
https://academic.o Is cholorquine better than Journal of up.com/jmcb/articl Chloroquine, Treating COVID‐19 with Mingxing lopinavir/ritonavir in Molecular Cell RCT China e/doi/10.1093/jmc NA lopinavir, Chloroquine Huang, et al. severe and moderate Biology ritonavir b/mjaa014/581465 COVID19 patients? 5
Compassionate Use of https://www.nejm. UK, Canada, 10 April 2020 NEJM Remdesivir for Patients Report Grein et al. org/doi/full/10.105 NA Remdesivir NA Europe, Japan with Severe Covid‐19 6/NEJMoa2007016
https://www.scien A systematic review on Summary of the existing Andrea cedirect.com/scien Journal of the efficacy and safety of Systematic the evidence on 10 March 2020 Italy Cortegiani, et ce/article/pii/S088 NA Chloroquine Critical Care chloroquine for the review chloroquine for the al. treatment of COVID‐19 3944120303907?vi treatment of COVID‐19 a%3Dihub
Systematic review of the Systematic review of the clinical outcomes of using efficacy and safety of Journal https://onlinelibrar antiretroviral drugs for antiretroviral drugs Systematic Antiretroviral Preprint International Switzerland N Ford et al. y.wiley.com/doi/10 NA the prevention and against SARS, MERS, or review drugs AIDS Society treatment of COVID‐19: initial .1002/jia2.25489 coronaviruses and assessment planned clinical trials Ethics committees of Hainan Investigate the effects of 6‐ General week respiratory Complementa Respiratory rehabilitation https://www.scien Hospital and Non‐ Respiratory rehabilitation training on ry Therapies in in elderly patients with cedirect.com/scien Huanggang 30 March 2020 interventional China Kai Liu, et al. rehabilitation respiratory function, QoL, Clinical COVID‐19: A randomized ce/article/pii/S174 Central RCT training mobility and psychological Practice controlled study Hospital 4388120304278 function in elderly (approval patients with COVID‐19 numbers: 19758 and 20200125)
Effects of progressive Progressive Investigate the effect of Complementa https://www.scien muscle relaxation on Non‐ muscle progressive muscle ry Therapies in cedirect.com/scien 6 March 2020 anxiety and sleep quality interventional China Kai Liu, et al. NA relaxation relaxation on anxiety and Clinical ce/article/pii/S174 in patients with COVID‐ RCT (sleep sleep quality of COVID‐19 Practice 19 4388120302784 therapy) patients
First Clinical Study Using https://www.medr HCV Protease Inhibitor Effect of danoprevir in xiv.org/content/10. danopevir/rito ############ MedRxiv Danoprevir to Treat CT China Chen et al. NCT04291729 moderate COVID‐19 1101/2020.03.22.2 navir Naïve and Experienced patients COVID‐19 Patients 0034041v1.full.pdf
The potential of low molecular weight heparin https://www.medr to mitigate cytokine Retrospective xiv.org/content/10. 07 April 2020 MedRxiv China Chen Shi et al. not found enoxaparin Efficacy of enoxaparin storm in severe covid‐19 CT 1101/2020.03.28.2 patients: a retrospective 0046144v2 clinical study
No evidence of clinical efficacy of hydroxychloroquine in https://www.medr To assess the patients hospitalised for effectiveness of Retrospective Matthieu xiv.org/content/10. Hydroxychloro 14 April 2020 MedRxiv COVID‐19 infection and France NA Hydroxychloroquine in analysis Mahévas et al. 1101/2020.04.10.2 quine requiring oxygen: results patients with severe Covid‐ of a study using routinely 0060699v1.full.pdf 19 collected data to emulate a target trial Grants: National Science and Technology Major Project (2018ZX10711 001, 2017ZX10103 011, 2017ZX10204 401), Sanming Project of Medicine in Treatment of 5 critically https://jamanetwo Shenzhen Is plasma from ill patients with COVID‐19 Observational rk.com/journals/ja (SZSM201412 Convalescent convalescente patients 27 March 2020 JAMA China C Shen, et al. with convalescent study ma/fullarticle/2763 003, plasma beneficial for critically ill plasma 983 SZSM2015120 COVID19 patients? 05), China Postdoctoral Science Foundation (2019T120147 , 2018M641508 ), Shenzhen Science and Technology Research and Proceedings of the National The feasibility of https://www.pnas. Is treatment with Observational Academy of convalescent plasma org/content/early/ ChiCTR200003 Convalescent convalescent plasma safe 6 April 2020 /retrospective China Kai Duan et al Sciences of therapy in severe COVID‐ 2020/04/02/20041 0048 plasma and beneficial for control the United 19 patients: a pilot study 68117 COVID19 patients? States of America
Compare medical masks Medical Masks vs N95 to N95 respirators in Respirators for Influenza and https://onlinelibrar preventing laboratory Preventing COVID‐19 in Jessica J N95 other Systematic y.wiley.com/doi/pd confirmed viral infection Preprint Health Care Workers ‐ A Canada Bartoszko, et NA respirators vs Respiratory review f/10.1111/irv.1274 and respiratory illness Systematic Review and al. surgical masks Viruses including coronavirus Meta‐Analysis of 5 specifically in health care Randomized Trials workers.
https://www.camb ridge.org/core/jour nals/disaster‐ medicine‐and‐ public‐health‐ RANDOMIZED TRIAL OF preparedness/artic Is attending one live INSTRUCTOR‐LED le/randomized‐trial‐ training session or TRAINING VERSUS VIDEO of‐instructorled‐ Disaster Training on watching video trainings LESSON IN TRAINING training‐versus‐ Medicine and L Christensen personal over a month more Preprint HEALTH CARE PROVIDERS RCT Denmark video‐lesson‐in‐ NA Public Health et al protective effective for training on IN PROPER DONNING Preparedness training‐health‐ equipment downing and doffing AND DOFFING OF care‐providers‐in‐ personal protective PERSONAL PROTECTIVE proper‐donning‐ equipment? EQUIPMENT and‐doffing‐of‐ personal‐ protective‐ equipment/CF08F4 727DA9D536883EC BFD04BC2570 Performance of VivaDiagTM COVID‐19 IgM/IgG Rapid Test is https://onlinelibrar Journal of Irene Diagnostic To assess an easy to inadequate for diagnosis Diagnostic y.wiley.com/doi/ep Preprint Medical Italy Cassantini et NA serological perform serological assay of COVID‐19 in acute assay df/10.1002/jmv.25 Virology al. assay for diagnosis of COVID19 patients referring to 800 emergency room department
DOI: 10.1128/ JCM.00461‐ 20; Hospital Ethics Evaluation of https://jcm.asm.or Committee of Joural of Nucleocapsid and Spike Diagnostic Evaluate the diagnostic Diagnostic Wanbing Liu, g/content/early/20 the General Preprint Clinical Protein‐based ELISAs for China serological feasibility of two ELISA assay et al. 20/03/27/JCM.004 Hospital of the Microbiology detecting antibodies assay assays Central against SARS‐CoV‐2 61‐20 Theater Command 107 of the PLA ([2020]003‐1)
Article Australian originally A cluster randomised New Zealand To compare the efficacy of published in trial of cloth masks https://bmjopen.b medical Australia MacIntyre CR Clinical Trials cloth masks to medical 2015; authors BMJ Open compared with medical RCT mj.com/content/5/ masks, cloth /Vietnam et al. Registry: masks in hospital added masks in healthcare masks 4/e006577 ACTRN126100 healthcare workers comment on workers 00887077. 30/03/2020
Efficacy of https://www.medr hydroxychloroquine in Zhaowei Chen xiv.org/content/10. ChiCTR200002 Hydroxychloro Assess the efficacy of ############ MedRxiv patients with COVID‐19: RCT China et al. 1101/2020.03.22.2 9559 quine hydroxychloroquine results of a randomized clinical trial 0040758v2
Clinical and microbiological effect of https://www.medit a combination of erranee‐ Assess the efficacy of Hydroxychloro hydroxychloroquine and infection.com/wp‐ hydroxychloroquine Preprint RCT France Gautret et al. NA quine, azithromycin in 80 COVID‐ content/uploads/2 associated with Azithromycin 19 patients with at least 020/03/COVID‐IHU‐ azithromycin a six‐day follow up: an 2‐1.pdf observational study
An exploratory randomized, controlled study on the efficacy and 23 March safety of https://www.medr Lopinavir‐Ritonavir 2020 lopinavir/riton lopinavir/ritonavir or xiv.org/content/10. combination compared to (preprint, not BMJ RCT China Li et al. NCT04252885 avir (Kaletra), arbidol treating adult 1101/2020.03.19.2 Arbidol compared to no yet peer‐ arbidol patients hospitalized antiviral treatment reviewed) 0038984v1 with mild/moderate COVID‐19 (ELACOI) ChiCTR200002 9939, ChiCTR200002 9935, ChiCTR200002 9899, ChiCTR200002 9898, ChiCTR200002 9868, ChiCTR200002 Breakthrough: 9837, Chloroquine phosphate https://www.jstag ChiCTR200002 has shown apparent Summary of e.jst.go.jp/article/b 9826, Could chloroquine be 10 Feb 2020 Biosci Trends efficacy in treatment of China Gao et al. Chloroquine 15 CTs st/14/1/14_2020.0 ChiCTR200002 effective? COVID‐19 associated 9803, pneumonia in clinical 1047/_article ChiCTR200002 studies. 9762, ChiCTR200002 9761, ChiCTR200002 9760, ChiCTR200002 9740, ChiCTR200002 9609, ChiCTR200002 9559, and
https://www.cytod Three Additional Patients yn.com/newsroom with Severe COVID‐19 Preliminary /press‐ not published Treated with Leronlimab results from releases/detail/401 Could leronlimab be ############ USA CytoDyn Inc. NA Leronlimab yet in New York Medical clinical trial /three‐additional‐ effective? Center Bringing the Total patients‐with‐ to 10 Patients severe‐covid‐19‐ treated‐with
https://www.medr Favipiravir versus Arbidol Chang Chen et xiv.org/content/10. ChiCTR200003 Favipiravir, Conventional therapy + ############ medRxiv for COVID‐19: A RCT China al. 1101/2020.03.17.2 0254 Arbidol favipiravir or arbidol? Randomized Clinical Trial 0037432v2
Hydroxychloroquine and International azithromycin as a https://www.scien EudraCT Hydroxychloro Role of Journal of treatment of COVID‐19: cedirect.com/scien ############ CT France Gautret et al. number 2020‐ quine, hydroxychloroquine on Antimicrobial results of an open‐label ce/article/pii/S092 000890‐25 Azithromycin respiratory viral loads Agents non‐randomized clinical 4857920300996#! trial
A Trial of Lopinavir‐ https://www.ncbi. Lopinavir‐Ritonavir Ritonavir in Adults ChiCTR200002 lopinavir/riton ############ N Engl J Med RCT China Cao et al. nlm.nih.gov/pubm combination compared to Hospitalized with Severe 9308 avir (Kaletra) conventional therapy ? Covid‐19. ed/32187464
Arbidol combined with https://www.scien LPV/r versus LPV/r alone cedirect.com/scien Arbidol and lopinavir‐ Journal of against Corona Virus Retrospective Lopinavir/rito ############ China Lisi Deng ce/article/pii/S016 NA ritonavir compared to Infection Disease 2019: A cohort study navir, Arbidol lopinavir‐ritonavir only? retrospective cohort 3445320301134?vi study a%3Dihub High‐flow nasal‐ oxygenation‐ assisted What is the efficacy and fibreoptic tracheal https://bjanaesthe safety of high‐flow nasal High‐flow British Journal intubation in critically ill Cai‐Neng Wu sia.org/article/S00 ChiCTR200002 oxygenation during In press RCT China nasal of Anaesthesia patients with COVID‐19 et al. 07‐0912(20)30135‐ 9658 fibreoptic bronchoscopic oxygnation pneumonia: a 5/fulltext intubation in critically ill prospective randomised patients with COVID‐19? controlled trial
Chinese Efficacy of lopinavir, http://rs.yiigle.com Efficacy of 2020 Pre‐print Journal of ritonavir and Arbidol for Retrospective Lopinavir/rito China Chen Jun et al. /yufabiao/1182592 NA lopinavir/ritonavir and online Infectious the treatment of new analysis navir, Arbidol arbidol Diseases, coronavirus pneumonia .htm
Journal of A pilot study of Zhejiang hydroxychloroquine in http://www.zjujour University Role of treatment of patients nals.com/med/CN/ Hydroxychloro 2020 (Medical RCT China Chen Jun et al. NCT04261517 hydroxychloroquine on with common 10.3785/j.issn.1008‐ quine Science) respiratory viral loads coronavirus disease‐19 2020 , Vol. 49 9292.2020.03.03 (COVID‐19) Issue (1)
Assess the efficacy and Meplazumab treats safety of meplazumab, a COVID‐19 pneumonia: an https://doi.org/10. Huijie Bian et humanized anti‐CD147 2020 Pre‐print MedRxiv open‐labelled, CT China 1101/2020.03.21.2 NCT 04275245 Meplazumab al. antibody, as add‐on concurrent controlled 0040691 therapy in patients with add‐on clinical trial COVID‐19 pneumonia.